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CHAPTER 1 
INTRODUCTION 
Current Status .of Caffeine 
Caffeine, (1,3,7-trimethylxanthine), is a xanthine 
derivative and occurs naturally in coffee beans, tea leaves, 
kola nuts, and cocoa beans found throughout the world (Syed, 
1976). As a result, caffeine is relatively accessible to 
all cultures. Caffeine has been described as the most 
widely consumed stimulant drug in the world (Chou, 1992). 
Adult intake of caffeine in the United States has been 
reported at approximately 2.5 milligrams per kilogram body 
weight (mg./kg. bwt.) or roughly 200 mg. per day (about two 
cups of coffee) and, for children 5 to 18 years old, the 
average daily caffeine intake is about 1.1 mg./kg. bwt. 
(Chou, 1992, p. 544). Furthermore, caffeine's stimulatory 
effects have been applied to both mental and physical per-
formance (Dodd, Herb, and Powers, 1993). 
Caffeine is consumed in food, beverages, prescription 
drugs, and over the counter (OTC) medications (Table I). 
For the average person, dietary caffeine intake is generally 
in the form of caffeinated beverages (e.g., coffee, tea, and 
colas) and chocolate with insignificant amounts of caffeine 
1 
2 
TABLE I 
CAFFEINE CONTENT OF SELECTED PRODUCTS 
*CAFFEINE CONTENT {MG) IN A 12 OZ. SOFT DRINK 
Afri-Cola 
Jolt 
Sugar-Free Mr. Pibb 
Mountain Dew 
Diet Mountain Dew 
Mello Yellow 
Tab 
Coca-Cola 
Diet Cola 
Shasta Cola 
Shasta Diet Cola 
Mr. Pibb 
Dr. Pepper 
Pepsi Cola 
Diet Pepsi 
RC Cola 
Diet RC 
Canada Dry Cola 
7 Up 
* National Soft Drink Association 
100.0 mg 
71.2 
58.8 
55.0 (O in Canada) 
55.0 
52.8 
46.8 
45.6 
45.6 
44.4 
44.4 
40.8 
39.6 
37.2 
35.4 
36.0 
36.0 
30.0 
0 
* Bunker, L., & Mcwilliams, M. (1979). Caffeine content 
of common beverages. =J-=o-=u=r=n=a=-=l=--=o:.::f:...-.::t=h=e::......:Am=e=r=1=· c=a=n=-=--=D-=i-=e-=t:.:e:...:t:.::i=-=c 
Association. 74. 28-32. 
*CAFFEINE CONTENT {MG) IN A 7 OZ. CUP OF COFFEE/TEA: 
Drip 
Espresso (1.5 - 2 oz.) 
Brewed 
Instant 
Decaf, brewed 
Decaf, instant 
Tea, iced (12 oz.) 
Tea, brewed, imported 
Tea, brewed, U.S. 
Tea, instant 
115-175 mg 
100 
80-135 
65-100 
3-4 
2-3 
70 
60 
40 
25-150 
* Bunker, L., & Mcwilliams, M. (1979). Caffeine content of 
common beverages. Journal of the American Dietetic 
Association. 74, 28-32. 
TABLE I {Continued) 
CAFFEINE CONTENT OF SELECTED PRODUCTS 
*CAFFEINE CONTENT (MG} IN SELECTED FOODS: 
Milk chocolate {l oz.) 1-15 mg 
Bittersweet chocolate (1 oz.) 5-35 
Chocolate cake {l slice) 20-30 
3 
* Health Letter Associates. {1990). The Daily Dose. Berk-
eley Wellness Letter, University of California. 
*CAFFEINE CONTENT (MG} IN A STANDARD DOSE 
OF NONPRESCRIPTION DRUGS: 
Stimulants 
Caffedrine Capsules 200 
NoDoz Tablets 200 
Vivarin Tablets 200 
Pain Relievers 
Anacin 64 
Excedrin 130 
Midol 65 
Aspirin 0 
Diuretics 
Aqua-Ban 200 
Permathene H20ff 200 
Pre-Mens Forte 100 
Cold Remedies 
Coryban-D 30 
Dristan 32 
Triaminicin 30 
Weight Control Aids 
Dexatrim 200 
Dietac 200 
Prolamine 280 
mg 
mg 
mg 
mg 
mg 
* Caffeine: How to consume less. {1981, October). Consum-
er Reports. 597-599. 
being provided in other foods flavored with coffee and 
chocolate (Graham, 1978). 
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Caffeine is widely used and very accessible to people 
of virtually every nation. These factors, combined with 
caffeine's stimulating effects, make the abuse of caffeine a 
potential problem for consumers of this drug. However, as 
E. M. Brecher and the editors of Consumer Reports (1972) 
point out, the majority of caffeine is consumed in such a 
way (e.g., dilution per serving based on preparation tech-
nique, addition of cream or milk, and/or ingestion following 
a meal) as to practically eliminate harmful side-effects. 
Therefore, serious abuse is not common. 
Caffeine has no nutritional value. However, due to its 
widespread use in society and ease of access, sports compet-
itors have and continue to explore caffeine's stimulatory 
effects on performance -- particularly improving mental 
outlook and reduction of fatigue (Powers & Dodd, 1985). In 
fact, caffeine is sometimes referred to as a "nutritional 
ergogenic aid" (Spriet, 1995, p.S84). Athletes, like the 
general population, consume caffeine in food, beverages, OTC 
medications, and prescription drugs (Table I). Since caf-
feine is consumed in many common foods, beverages, and 
medications, the International Olympic Committee (IOC) 
removed caffeine from its list of doping agents in 1972 
(VanHandel, 1983). Later, however, the IOC did ban "high 
levels" of caffeine administered by injection or suppository 
(VanHandel, 1983). Then, in 1982, caffeine was once again 
added to the IOC's list of doping agents with a limit of 15 
micrograms per milliliter (µg./ml.) (about 10 cups of cof-
fee). In time, this limit was lowered to 12 µg./ml. (Catin 
& Hatton, 1991). 
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Caffeine's stimulatory effects have and continue to be 
examined. Much emphasis has been placed on this drug's 
impact on motor performance and on the subject's state of 
alertness. However, for many occupations (e.g., pilots, air 
traffic controllers, professional athletes, computer pro-
grammers, and data entry) the effects of caffeine on vision 
may have just as big an impact. The need exists for further 
research to be conducted on the effects of caffeine on 
vision to further illuminate the potential relationship 
between caffeine consumption and professional, vocational, 
and even recreational visual performance. Caffeine's effect 
on luminescent threshold comparisons, flicker fusion dis-
crimination, and repetition blindness may provide this type 
of information. Despite what the results may reveal, the 
general public, employers, and employees have the right to 
benefit from such information whether from a recreational or 
occupational viewpoint. 
Properties of the Drug 
Caffeine, a xanthine derivative, is an odorless, bit-
ter, white, crystalline powder. Its' chemical structure is 
6 
identified as 1,3,7-trimethylxanthine (Figure 1). Caffeine 
empties rapidly from the stomach and is absorbed by the 
gastrointestinal tract. The highest levels of caffeine are 
generally detected in the blood stream approximately one 
hour following ingestion with the most caffeine being 
delivered to tissue with high water content (e.g., muscle 
tissue) (Axelrod & Riechenthal, 1953). Therefore, the ef-
fects produced is directly proportional to the concentration 
of caffeine in various body tissues (VanHandel, 1980). 
Caffeine is efficiently metabolized by the liver pre-
venting accumulation in organs or tissues. This metaboliza-
tion varies in rate evidenced by caffeine's half-life (the 
time required for the drug to be eliminated) ranging from 2 
to 12 hours with an average half-life of 4 to 6 hours (Chou, 
1992). Longer half-lives are generally experienced by 
pregnant women, women taking oral contraceptives, consump-
tion of alcohol, and persons suffering from liver disease. 
Conversely, smokers metabolize caffeine more quickly thereby 
experiencing shorter half-lives. (Sawynok, 1995). Approxi-
mately 2% to 3% of the ingested caffeine is excreted un-
changed in the urine (Chou, 1992). 
Caffeine produces pharmacological responses in various 
systems of the body. Caffeine stimulates the central ner-
vous system often resulting in heightened alertness and 
clarity of thought (Syed, 1976). As a result of these 
effects on the central nervous system, caffeine may indeed 
7 
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Figure 1. Chemical Stractme of Ca.treine 
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act on the muscular system by increasing motor activity. On 
the other hand, caffeine's effect on the central nervous 
system has been reported to aggravate psychiatric disease 
(Chou, 1992). High doses of caffeine (>600 mg. per day) 
produces a condition identified as "caffeinism". Caffeinism 
is characterized by anxiety, sleep disorders, and states of 
restlessness, which is often characteristic of anxiety 
disorders (Greden, 1974). 
The stimulating effect of caffeine is apparent on the 
cardiovascular system as evidenced by increased heart rate. 
This increase, however, is generally preceded by a decrease 
in heart rate due to simultaneous stimulation of medullary 
vagal nerves (Maccornack, 1977). _ Increases in vasodilation, 
coronary circulation, and/or increased blood pressure are 
also common physiological responses following caffeine 
ingestion. Caffeine has reportedly effected vision by 
increasing intraocular pressure under certain conditions 
(Higginbotham, Kilimanjaro, Wilensky, Batenhorst & Hermann, 
1989), improving visual monitoring (Putz-Anderson, Setzer & 
Croxton, 1981), increasing the eye's susceptibility to light 
(Diamond & Cole, 1970), and improving visual reaction time 
(Leiberman, Wurtman, Emde & coveilla, 1987). Similarly, 
caffeine stimulates the kidneys causing the urinary system 
to increase urination. The digestive system is also acti-
vated as indicated by an increase in the secretion of gas-
tric acids (Brecher, 1972). In addition, caffeine has been 
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reported to stimulate the respiratory system by increasing 
the rate and depth of respiration. There have also been 
reports of an effect on the endocrine system involving 
stimulation of the adrenal glands (VanHandle, 1983). All in 
all, caffeine has been described as increasing the body's 
metabolic rate. 
These potential outcomes can explain the use of caf-
feine as an ergogenic aid despite equivocal research re-
sults. Particularly when caffeine's effects on the central 
nervous system, cardiovascular system, muscular system, 
endocrine system, and vision are considered, the potential 
for improved physical performance is clear. However, this 
ergogenic activity continues to be questioned and examined. 
Caffeine does serve several therapeutic uses in the 
medical field today (Sawynok, 1995). Caffeine, in conjunc-
tion with other drugs, have been used to treat headaches and 
pain. This drug has been utilized to stimulate the respira-
tory systems of premature infants and to lengthen seizure 
duration needed in electroconvulsive therapy to treat cer-
tain types of depression. In addition, caffeine has been 
used to treat hypotension in the elderly following food 
ingestion and in the treatment of obesity. However, the 
ingestion of caffeine has been linked to several negative 
side effects as well. 
Negative side effects associated with caffeine intake 
include: diuresis, insomnia, withdraw! headaches, diarrhea, 
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anxiety, tremulousness, and irritability (VanHandle, 1983). 
These noxious effects have been reported to occur with 
intake greater than 1 gram of caffeine (7 to 10 cups of 
coffee) (Brecher, 1972). However, such effects have also 
been reported with caffeine intake as low as 250 mg. (2 to 3 
cups of coffee) (Sawynok, 1995). A lethal dosage has been 
estimated to be approximately 10 grams of caffeine or ap-
proximately 70 to 100 cups of coffee (Brecher, 1972); al-
though death caused by caffeine intake is rare. Caffeine 
effects are obviously going to be dependent on the subject's 
sensitivity to the drug, the weight/muscle mass of the 
subject, the form in which caffeine is consumed, and the 
subject's tolerance level. 
Long term use of caffeine has been the topic of much 
interest over the years. Caffeine intake has been linked to 
heart attacks, hypertension, birth defects, colorectal 
cancer, and pancreatic cancer. In spite of much conjecture, 
no significant relationship has been statistically identi-
fied between these diseased states and moderate caffeine 
intake (approximately 5 cups of coffee per day). The one 
exception reported by Sawynok (1995) is that there is an 
elevated risk of bladder cancer observed in coffee drinkers; 
however, coffee has not been identified as the cause. 
Regular consumption of caffeine, like many other drugs, 
can produce tolerance to this stimulant. This process is 
still unclear (Sawynok, 1995). However, when the level of 
11 
consumption is decreased or terminated, withdrawal symptoms 
generally result. These symptoms include headaches, irrita-
bility, inability to concentrate, nervousness, and lethargy 
(Brecher, 1972). After time, these symptoms will dissipate 
as dependence on this stimulant dissipates. Or, if addi-
tional caffeine is consumed, the withdraw! symptoms will be 
postponed indefinitely. 
Caffeine's effects on the central nervous system have 
been the focus of much research during past decades. Due to 
the stimulating effect caffeine has on the central nervous 
system, many studies have extended this application to other 
systems of the body including the endocrine system, muscular 
system, respiratory system, cardiovascular system, and even 
to caffeine's effects on vision. However, studies address-
ing the effects of caffeine on vision are not as numerous or 
as extensive as research dealing with caffeine and other 
body systems. Additional work is needed to fully examine 
this drug's effect on vision. As a result, caffeine's 
effect on luminescent threshold comparisons, flicker fusion 
discrimination, and repetition blindness will be examined. 
Purpose of the study 
The intent of this study was to investigate the influ-
ences of two doses of caffeine (2.5 mg./kg. bwt., and 5.0 
mg./kg. bwt.) and a placebo on three aspects of vision: 
luminescent threshold comparisons, flicker fusion discrimi-
12 
nation, and repetition blindness. 
Hypotheses 
The following hypotheses were examined in this investi-
gation. 
HOl: There will be no ·difference between pre-test and 
post-test luminescent threshold responses at the "low" 
luminescence setting after consumption of placebo, 2.5 
mg./kg. bwt., and 5.0 mg./kg. bwt. caffeine. 
H02: There will be no difference between pre-test and 
post-test luminescent threshold responses at the "moderate" 
luminescence setting after consumption of placebo, 2.5 
mg./kg. bwt., and 5.0 mg./kg. bwt~ caffeine. 
HOJ: There will be no difference between pre-test and 
post-test luminescent threshold responses at the "high" 
luminescence setting after consumption of placebo, 2.5 mg./-
kg. bwt., and 5.0 mg./kg. bwt. caffeine. 
H04: There will be no difference between pre-test and 
post-test flicker fusion responses after consumption of 
placebo, 2.5 mg./kg. bwt., and 5.0 mg./kg. bwt. caffeine. 
HOS: There will be no difference between pre-test and 
post-test repetition blindness responses after consumption 
of placebo, 2.5 mg./kg. bwt., and 5.0 mg./kg. bwt. caffeine. 
Delimitations 
1. A total of 23 subjects (9 male and 14 female) were 
used in this study. 
2. All subjects were healthy college students from 
Oklahoma State University. 
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3. There were three levels of treatment administered: 
2.5 mg./kg. bwt.; 5.0 mg./kg. bwt.; and placebo. 
4. The subjects for this investigation were not ran-
domly selected. 
5. All subjects were classified as average caffeine 
consumers consuming approximately 200 mg. per day{± 200 
mg.) . 
Limitations 
1. There may have been individual sensitivity to caf-
feine. 
2. Fluctuations in electrical voltage may have pre-
vented the absolute value of the Light Discrimination 
Apparatus and the Visual Perception Control from being 
accurately determined. 
Assumptions 
1. Subjects correctly followed all instructions. 
2. Subjects consumed all caffeine with tap water. 
3. Subjects were honest in their initial estimation of 
caffeine consumption prior to the study. 
4. Subjects• responses represent their best effort to 
correctly respond to each test. 
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Definition of Terms 
Luminescent Threshold is the point in time at which the 
eye can discern the most minute difference in the intensity 
of light acting as a stimulus. 
Flicker Fusion is the point in time where the frequency 
of a flickering light is no longer discernable; the light 
"fuses" into continuous illumination. 
Repetition Blindness is the inability to identify a 
second exposure to a repeated word or identification of a 
novel word following an initial exposure to a prime word. 
CHAPTER II 
REVIEW OF LITERATURE 
Introduction 
Caffeine is one of the most commonly used drugs. It is 
consumed in beverages, foods, prescription drugs, and over 
the counter medications. As a result, it effects various 
systems of the body and produces both positive and negative 
results. Since the body is comprised of these "various 
systems", the effects are often cumulative and far reaching. 
To better understand the influence of caffeine on selected 
systems, this review will focus on three primary areas: 
neurological effects, neuromuscular effects, and the effects 
of caffeine on vision. 
Neurological Effects 
Caffeine acts as a central nervous system stimulant. 
After easily passing the blood/brain barrier, caffeine acts 
on the cerebral cortex (Syed, 1976). The cerebral cortex 
covers masses of nerve fibers connecting the cortex with 
other parts of the nervous system (Hole & Koos, 1991). So 
in addition to resulting in clearer thought, sharpened 
cognitive abilities, and a decline in drowsiness and fa-
15 
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tigue, Syed (1976) further describes caffeine as directly 
effecting the brain's medullary, vasomotor, respiratory, and 
vagal centers. 
Four primary mechanisms have been hypothesized to 
explain caffeine's effect on the central nervous system at 
the cellular level (Nehlig, Duval & Debry, 1992). The first 
mechanism is identified as "intracellular mobilization of 
calcium". This intracellular mobilization was initially 
examined in skeletal muscle fibers (Bianchi, 1975; VanHand-
le, 1983). Caffeine (1 to 2 millimoles (mM)) has been 
reported to lower the muscle cell's excitability threshold 
and increases the length of the contraction by movement of 
calcium through the plasma membrane and from the sarcoplas-
mic reticulum (Bianchi, 1975). Investigating this concept 
with a more broad application revealed that synaptic trans-
mission in the central and peripheral nervous systems 
requires neurotransmitter release which is dependent on the 
incursion of calcium into nerve endings (Nehlig et. al., 
1992). However, a minimum caffeine concentration of 250 
micromoles (µM) (2.5 to 7.5 cups of coffee) is necessary to 
produce these calcium shifts (Guthrie & Naylor, 1967) and 
pharmacological effects of caffeine are generally detected 
by concentrations lower than 100 µM (1 to 3 cups of coffee). 
As a result, it seems unlikely that "intracellular mobiliza-
tion of calcium" is an integral role of caffeine on the 
central nervous system (Nehlig et. al., 1992). 
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A second hypothesis developed to explain caffeine's 
effect on the central nervous system was "inhibition of 
phosphodiesterase". Through a series of cellular reactions, 
adenosine 3',5'-cyclic monophosphate or cyclic AMP (cAMP) 
plays a vital role in controlling glycogen metabolism and 
peripheral lipolysis. Phosphodiesterase, an enzyme, breaks 
down cAMP. Caffeine (methylxanthines) prevents enzymatic 
breakdown of cAMP through inhibition of phosphodiesterase 
thereby decreasing glycogenolysis and promoting lipolysis 
(Beavo et al., 1970; Dodd et al., 1993). However, caf-
feine's effects on phosphodiesterase are produced only when 
the methylxanthine is present in very large quantities (1 
mM); quantities that are considered toxic (Cardinali, 1980). 
Therefore, it is difficult to associate the "inhibition of 
phosphodiesterase" with concentrations of caffeine found in 
circulating blood. 
"Antagonism of adenosine receptor sites" is a third 
hypothesis explaining caffeine's effect on the central 
nervous system. Adenosine is a normal cellular constituent 
and it is also commonly found in extracellular fluid. 
Adenosine is defined by VanHandel (1983) as being a "neuro-
transmitter or modulator with depressant, hypnotic, and 
anticonvulsant properties" (p. 133). These depressant 
results are quite extensive since adenosine receptors are 
located throughout the body. This third hypothesis, howev-
er, depicts caffeine (methylxanthines) blocking the stimu-
18 
lation of cAMP formation by blocking adenosine receptor 
sites {Sattin & Rall, 1970; VanHandle, 1983). As a result, 
following caffeine consumption, people experience wakeful-
ness, increased energy and increases in locomotor activity 
rather than lethargy, drowsiness, and decreases in activity 
level. Low plasma concentrations {less than 100 µM, which 
is equal to drinking 1-3 cups of coffee) of caffeine {methy-
lxanthines) have been found to antagonize adenosine receptor 
cites {Nehlig, et. al., 1992). In addition, caffeine at 
such low concentrations appears to have no direct effect on 
metabolism of cAMP or on calcium shifts {Snyder, Katims, 
Annau, Bruns & Daly, 1981). 
A fourth hypothesis, "interactions with benzodiazepine 
binding sites" has been considered. Benzodiazepines act as 
depressants producing minimal decreases in blood pressure 
and cardiac output with dose related reductions in blood 
flow to the brain and utilization of oxygen. Similarly, 
skeletal muscles experience mild relaxant effects {Stoelt-
ing, 1991). Caffeine binds to benzodiazepine receptor 
sites; however, it is not a strong bond {Boulenger, Patel & 
Marangos, 1982). Caffeine is a much stronger antagonist of 
adenosine receptor sites than those of benzodiazepine. As a 
matter of fact, the effect of caffeine on benzodiazepine 
receptor may actually be due to caffeine's effect on adeno-
sine receptors. In addition, it has been proposed that 
caffeine's influence on benzodiazepine receptors would only 
occur at toxic levels of caffeine consumption (Davies & 
Chow, 1984). 
19 
Four mechanisms that have been hypothesized to explain 
caffeine's effect on the central nervous system at the 
cellular level. However, of the four, only one explanation 
has withstood the test of time. Currently, the most common-
ly accepted explanation of caffeine's effect on the central 
nervous system is the "antagonism of adenosine receptor 
sites" (Daly, Bruns & Snyder, 1981; Dodd et al, 1993; Fred-
holm, 1995; Graham, Rush, & vansoren, 1994). 
Caffeine's effects have even broader applications. 
This methylxanthine may have potential effects on the cen-
tral nervous system involving neurotransmitters (e.g., 
catecholamines, serotonin, acetylcholine, and amino acids). 
In addition to being dependent on calcium shifts as men-
tioned earlier, elevated levels of neurotransmitters are 
also linked with altered substrate mobilization; increased 
lipolysis and decreased glycolysis. A potential role of 
adenosine in the central nervous system is to suppress the 
release of numerous neurotransmitters. Consequently, adeno-
sine antagonists (methylxanthines such as caffeine), theo-
retically, would be expected to increase neurotransmitter 
release thus altering substrate utilization (Chow, 1992; 
Graham et al., 1994; Nehlig et al., 1992; VanHandel, 1980). 
Caffeine effects cerebral blood flow and the utiliza-
tion of glucose. Caffeine precipitates changes in cerebral 
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energy metabolism by way of increased usage of glucose. 
This increased metabolism may ultimately effect spontaneous 
motor activity, simple and complex coordination, endurance 
and athletic performance, aggressiveness and mood, anxiety 
and sleep, and learning and memory. As mentioned earlier, 
caffeine is classified as a central nervous system stimu-
lant. Methylxanthines, in general, produce vasodilation. 
However, rather than causing vasodilation of cerebral vascu-
lature as would be expected of this type of stimulant, 
caffeine ingestion results is vasoconstriction of these 
vessels thus decreasing cerebral blood flow. Oddly enough, 
this reduction of blood flow generally occurs in areas of 
the brain where caffeine is simultaneously increasing metab-
olism. Cerebral blood flow is generally closely matched 
with glucose usage. When cerebral activity changes, these 
changes cause parallel shifts in blood flow and glucose 
utilization. However, counter to the effects of other 
methylxanthines, caffeine causes a reduction in cerebral 
blood flow while simultaneously increasing glucose metabo-
lism (Nehlig et al., 1992). 
All of caffeine's effects on the central nervous system 
are relayed to the peripheral nervous system via somatic 
fibers connecting to the skin and skeletal muscles and 
autonomic fibers connecting to the visceral organs. In 
addition, this autonomic nervous system further relays im-
pulses to its two subdivisions. The sympathetic division 
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basically prepares the body for stress (e.g., emergencies) 
and the parasympathetic division is most active under ordi-
nary conditions. In this way, the effects of caffeine on the 
central nervous system is transmitted to the periphery as 
well; thereby having the potential to effect metabolism, as 
well as, behavior and performance (Hole & Koos, 1991). 
Neuromuscular Effects 
Caffeine distribution in the body is dependent on the 
water content of body tissues. Therefore, skeletal muscle, 
possessing a high water content, generally exhibits elevated 
caffeine levels following ingestion. According to Dodd et 
al. (1993), caffeine potentially effects skeletal muscle 
through three possible mechanisms: increased affinity of 
myofilaments for calcium and/or increased calcium release 
from the sarcoplasmic reticulum; changes in cellular activ-
ity due to an increase in cAMP in skeletal muscle tissue; 
and inhibition of adenosine receptor sites in the central 
nervous system. 
The first mechanism often considered in the explanation 
of caffeine's effect on skeletal muscle involves myofilam-
ents developing a greater affinity for calcium and/or caus-
ing an increase in the calcium release from the sarcoplasmic 
reticulum following caffeine ingestion. The idea of caf-
feine enhancing the mobilization of intracellular calcium 
from membrane stores was very popular in the 1960 1 s (Bian-
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chi, 1961). Additional studies on isolated skeletal muscle 
have repeatedly shown caffeine's effects. Caffeine causes 
translocation of calcium through plasm and the membranes of 
the sarcoplasmic reticulum thereby lowering the threshold 
potential for excitation and extending the active period of 
muscle contraction (Fryer & Neering, 1989; Su & Hasselbach, 
1984; VanHandel, 1983). Similarly, increased myofibrillar 
sensitivity to caffeine is evidenced by a greater twitch 
tension development at submaximal calcium concentrations 
(Gulati & Babu, 1985; Wendt & Stephenson, 1983). 
A second mechanism developed to explain caffeine's 
effect on skeletal muscle involves increased levels of cAMP 
causing changes in the activity of the cell. Caffeine may 
actually alter both lipid and carbohydrate storage in skele-
tal muscle (VanHandel, 1983). As mentioned earlier in 
"Neurological Effects", caffeine increases cellular levels 
of cAMP. Increased cAMP has been shown to increase glyco-
genolysis resulting in hyperglycemia (MacCornack, 1977; 
Syed, 1976; VanHandel, 1983). As in the case with most 
activities, glycogen (carbohydrate) generally serves as the 
initial substrate utilized in transforming chemical energy 
to mechanical energy. Therefore, this initial increase in 
glycogenolysis serves a very useful purpose. Increased cAMP 
also promotes lipolysis (VanHandel, 1983). Increased lipol-
ysis boosts the free fatty acids available as a substrate 
for contracting muscles; however, increases in fatty acid 
oxidation generally surpass and slow the rate of carbohy-
drate utilization (Dodd et al., 1993; VanHandel, 1980; 
VanHandel, 1983). This increase of free fatty acids and 
sparing of glycogen during exercise could theoretically 
improve performance in endurance activities (Dodd et al., 
1993; VanHandel, 1980). 
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The third mechanism explaining caffeine's effect on 
skeletal muscle refers to inhibition of adenosine receptor 
sites in the central nervous system with related effects 
occurring in peripheral cells (Fredholm, 1985; Zhang & 
Wells, 1990). Adenosine, via interaction with adenosine 
receptors, is involved with regulation of almost every organ 
system (e.g., neurotransmitter release, control of smooth 
and cardiac muscle tone, formation of white blood cells and 
platelets, and adipose tissue lipolysis) (Olson & Pearson, 
1990; Ramkumar, Bumganer, Jacobson & Stiles, 1988). Initial 
research conducted by Sattin and Rall (1970) on slices of a 
guinea pig's cerebral cortex exhibited a decrease of cAMP 
levels following ingestion of 0.5 mM methylxanthines. 
Further studies conducted which resulted in blocked adeno-
sine receptor sites in brain tissue by caffeine resulted in 
stimulation of behavior (Holtzman, Mante & Minneman, 1991). 
Similarly, Zhang and Wells (1990) reported a reduction of 
triglyceride content in adipocytes of caffeine treated rats 
inferring increased lipolysis. 
It seems logical to expect much of the information pro-
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vided in the previous section, "Neurological Effects", would 
apply to the skeletal muscles since the muscles receive 
stimuli from the central nervous system by way of the pe-
ripheral nervous system. For example, studies reporting in-
creased lipolysis could, and often do, reflect alterations 
in substrate utilization by skeletal muscle. However, very 
few studies have correlated antagonism of adenosine recep-
tors directly with skeletal muscle effects. Challis, Rich-
ards, and Budohoski (1992) conducted a study directed at 
examining adenosine receptors located in the skeletal muscle 
of rats. These findings did support the proposal that 
adenosine does have an insulating modulating action in 
skeletal muscles• transport of giucose more so than skeletal 
muscles• stimulation of glycogen synthesis and this activity 
is mediated by adenosine receptors. But, no new information 
concerning the importance of adenosine receptors was uncov-
ered. Consequently, the lack of new information concerning 
skeletal muscle response to caffeine's antagonistic effects 
on adenosine receptors combined with the known effects of 
caffeine on the central nervous system and other organ 
systems leaves many questions unanswered. However, evidence 
does suggest that inhibition of adenosine receptors is one 
of the most important, if not the most important, mechanisms 
utilized to explain the physiological effects of caffeine at 
nontoxic concentrations (Dodd et al., 1993). 
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Visual Effects 
Caffeine's stimulating effects are conveyed systemical-
ly to all parts of the body (Koetting, 1977). Since caf-
feine does stimulate certain medullary centers, the eye is 
susceptible to drugs that affect the central nervous system 
through systemic circulation. And, due to an ample number 
of vessels providing a very rich blood supply to this organ 
that is relatively small in mass, the eye exhibits increased 
sensitivity to many drugs. Adverse effects generally occur 
with high doses with more intense reactions occurring in 
individuals with heightened sensitivity and in the very 
young and old. (Jaanus, 1992) 
The effect of caffeine on different structures in the 
eye has been the focus of several studies. Lotfi and Grunw-
ald (1991) studied the effects of caffeine (200 mg.) on 
retinal circulation and the results point to a presumed 
decrease in blood flow despite an increase in diastolic 
blood pressure. This result led the researchers to attrib-
ute the decreased circulation to retinal vasoconstriction 
brought on by inhibition of endogenous adenosine. Another 
study conducted by Higginbotham et al. (1989) investigated 
the effect of drinking regular coffee on intraocular pres-
sure in subjects with glaucoma. These authors found that 
caffeine (505.8 ± 19.45 µ.g/ml) did have a statistically 
significant effect on intraocular pressure when compared to 
caffeine-free beverages 90 minutes after ingestion but not 
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at the JO and 60 minute intervals. In addition, caffeine 
had a statistically significant effect on diastolic pressure 
at both the 60 and 90 minute intervals. However, neither of 
these findings were found to be clinically significant. 
Examination of changes in pulse rate and systolic pressure 
were both found to be statistically insignificant. There-
fore, according to these authors, there is no reason to 
limit/control caffeine consumption among glaucoma patients. 
Adams and Brubaker {1990) also conducted a study on the 
eye's intraocular pressure. However, in this study, appar-
ently healthy subjects were orally administered caffeine 
(400 mg.). Findings showed no statistically significant 
difference in aqueous humor flow measured hourly from 1 to 4 
hour after caffeine ingestion. Similarly, there was no 
statistically significant difference in intraocular pressure 
measured 4 hours after caffeine ingestion. Again, there was 
no evidence to suggest that average or slightly above aver-
age daily caffeine consumption produces a clinically signif-
icant effect on intraocular pressure. 
Studies addressing the effects of caffeine on the 
ability of the eye to function are also very common. As 
early as 1959, John Carpenter {1959) examined the effect of 
caffeine and alcohol on simple visual reaction time. His 
findings do suggest that high doses caffeine (2.94 mg./kg. 
bwt.) do produce significant reductions in reaction time; 
particularly when reaction times have been lengthened by the 
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consumption of alcohol. However, this particular study 
(Carpenter, 1959) could not substantiate this hypothesis. 
More recently, Leiberman et al. (1987) discovered that caf-
feine equivalent to that found in a single serving of cola 
(32 to 64 mg. of caffeine) significantly improved auditory 
vigilance and visual reaction time. No adverse behavioral 
effects were reported even at the highest dose administered 
( 64 mg.) . 
Broverman and Casagrande (1982) studied the effects of 
caffeine (113 mg.) on tasks requiring perceptual-restruc-
turing at different stages of practice. Caffeine tends to 
impair perceptual-restructuring task performance when the 
tasks are novel, and tends to facilitate performance of 
tasks that are not novel. In other words, caffeine was 
found to both facilitate and impair performance of these 
restructuring tasks. The effect was dependent on the stage 
of practice. A recent study (Kenemans and Lorist, 1995) 
examined the effects of caffeine (3 mg./kg. bwt.) on selec-
tive visual processing. The effects on visual processing 
was revealed utilizing five parameters: modifications in 
EEG indicating a change in brain state; improved performance 
in a simple selective attention task; increased selectivity 
of processing; improved task-independent discrimination of 
stimuli; and accelerated central motor processes. The 
findings included: (a) cortical activation increased 
following caffeine ingestion; (b) caffeine increased sensi-
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tivity, or the rate at which information on the stimulus 
accumulates; (c) caffeine increased selectivity, in particu-
lar with respect to further processing of stimuli once 
selected on the basis of the primary attribute; however, 
these findings suggest further research is needed; (d) 
caffeine speeded up central or peripheral motor processes. 
The effect of caffeine on visual tracking has been 
another topic of interest. Baker and Theologus (1972) 
studied the effects of caffeine (200 mg. and 400 mg.) on a 
protracted visual monitoring task similar to an aspect of 
automobile night driving. The results indicated that caf-
feine (both dosages) significantly inhibited response block-
ing or, in the case of automobile driving, attention lapses. 
Similarly, in a study conducted by Putz-Anderson et al. 
(1981) examining the effects of caffeine (3 mg./kg. bwt.), 
alcohol and methyl-chloride on man, the protocol included a 
visual vigilance task and a dual task comprised of tone-
detection and eye-hand compensatory tracking. The subjects 
who received the caffeine showed a 4% improvement over the 
control group on the vigilance task. In the dual task, only 
the tracking activities were sensitive to the effects of 
caffeine treatment. When tracking activities during the 
caffeine treatment were compared with the pretreatment 
scores, tracking error decreased by an average of 10% 
(p<.05). Improved visual tracking caused by caffeine and 
nicotine in rats was compared to the effects of amphetamine, 
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cocaine, and apomorphine by Evenden, Turpin, Oliver, and 
Jennings (1993). In examining the caffeine-specific data 
generated among a wealth of statistics in this comparison, 
caffeine reduced the rate of responding at the highest 
caffeine dose (30 mg./kg.). Caffeine also increased track-
ing efficiency at the two highest doses (10 mg./kg. and 30 
mg./kg.). 
Visual vigilance is another related ability effected by 
caffeine. Lake and Meliska (1984) examined the effects of 
caffeine on protracted visual vigilance tasks. Higher caf-
feine users (mean= 204±84 mg./day) made significantly fewer 
hits, more false alarms, and responded faster than lower 
caffeine users (mean= 44±28 mg./day). Performance declined 
during the 90 minutes of vigilance testing. No improvement 
was found in vigilance relative to caffeine ingestion; which 
opposes expected results based on previous test results 
utilizing various methodology. Caffeine did not reverse 
progressively deteriorating performance relative to control. 
Similarly, Fine et al.(1994) examined the effects of caf-
feine (200 mg.) or diphenhydramine on visual vigilance. 
However, as opposed to Loke and Meliska'a study (1984), 
caffeine significantly increased the number of correct 
responses and decreased response times when compared to the 
placebo. Low habitual consumers of caffeine (<100 mg./day) 
and nonsmokers had more correct responses than did high 
habitual caffeine consumers (> 100 mg./day), but only in the 
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placebo condition. Fine et al. {1994) addresses the fact 
that these findings oppose those of Loke and Meliska {1984) 
and points out that the discrepancy may be due to the nature 
of their task and not an absence of an underlying effect. 
William Pare (1961) examined the retroactive effects of 
caffeine (30 mg./kg. bwt.) and seconal on learning in the 
early 1960 1 s. Utilizing a visual discrimination apparatus 
rats were required to discriminate between different colored 
cards after training. Results indicated that the rats who 
received caffeine injections manifested fewer errors on 
retention trails than those receiving seconal or placebo. 
Further, the number of errors on retention trials for these 
rats were positively related to the learning criterion-
injection interval; caffeine injections 5 seconds after 
criterion made significantly fewer errors on retention 
trials whereas injections at 2 minutes and 1 hour following 
criterion did not produce significant differences. 
The relationship between the effects of caffeine and 
fatigue is a very interesting association. Lorist was the 
primary investigator in two studies examining the effects of 
caffeine and fatigue. In the first study, Lorist, Snel, and 
Kok {1994) examined the effects of caffeine (200 + 50 mg., a 
maintenance dose) on information processing in well rested 
and fatigued subjects. Data showed that caffeine shortened 
reaction time with an accompanying interaction with stimulus 
degradation and time uncertainty in the majority of sub-
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jects. In addition, the idea of caffeine increasing corti-
cal arousal and perceptual sensitivity was supported. 
Fatigued subjects showed larger improvements in performance 
following caffeine consumption than did well rested sub-
jects. These findings also indicate that the effects of 
caffeine were not stimulating in all subjects. Six out of 
30 subjects showed no arousing effects of caffeine. In the 
second study, Lorist, snel, Kok, and Mulder (1994) examined 
the influence of caffeine (200 + 50 mg., a maintenance dose) 
on selective attention utilizing a visual focused selective 
search task in well-rested and fatigued subjects. The 
findings depicted subjects reacting faster after having 
consumed caffeine. Reaction times in the caffeine condition 
were significantly shorter than those in the placebo condi-
tion (p<.02). Additionally, in the test focusing on target 
detection, caffeine's effects were dependent on the state of 
the subject. The author's hypothesized that the quality and 
speed of stimulus perception and decision to respond may be 
adversely effected by fatigue. 
All of the information previously discussed helps to 
explain caffeine's effect on the body -- particularly neuro-
logically, neuromuscularly, and visually. Specifically, 
this study's focus is directed at caffeine's effects on 
three selected visual components: luminescent threshold 
comparisons, flicker fusion discrimination, and repetition 
blindness. 
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Luminescent threshold comparisons were examined by 
Kleman, Diamond, and Smith (1961) while observing the ef-
fects of caffeine on "foveal simultaneous contrast". The 
researchers utilized an apparatus that implemented a chin 
rest (122 cm. from the apparatus), a center baffle that 
separated right and left visual pathways, two different 
visual patterns (one to be viewed by the right eye and a 
different pattern for the left eye), a small circular test 
field surrounded by an inducing annulus, and separate light 
sources, 100 watts (w.) and 120 volts (v.), for each eye. 
Data was collected from three subjects who were low to 
moderate caffeine users and who had been instructed to 
abstain from caffeine for 24 hours prior to testing. 
Testing was conducted on two separate days. On each test 
day, subjects were administered two levels of treatment 
(placebo and then caffeine) with one visual test being 
administered after the other. The placebo was administered 
to the subjects followed by a 15 minute rest period and 
another 15 minutes of dark adaptation (30 minutes total) 
prior to testing. The same procedure was then repeated with 
a standard 3 grains (194.4 mg.) of caffeine. The effect of 
caffeine was reported in log millilamberts (log mL) as a 
function of the inducing field luminance and plotted as a 
function of the log luminance. 
The results of this testing showed that the subjects' 
responses following caffeine intake not only reduced the en-
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hancement phenomenon (test field brightness being perceived 
as brighter when the inducing luminance is less than the 
test luminescence) but actually erased it so that the 
brightness of the test field was depressed in direct propor-
tion to the luminance of the inducing field. Depression of 
the test field (perceived when the inducing luminance is 
equal to or greater than the test luminance) continued to 
occur similar to the non-drug state. A mechanism identified 
to possibly explain this lack of enhancement was that the 
"on" retinal fibers became more sensitive with caffeine and 
depression of the test field occurred which reduced or 
eliminated enhancement. 
Diamond and Cole (1970) expanded on the work of Klemen 
et al. (1961) and examined visual threshold as a function of 
test area and caffeine administration. The threshold 
luminance of a circle was measured in relation to its' area 
before and after ingestion of placebo, 1.5 grains (97.2 mg.) 
of caffeine, and 3.0 grains (194.4 mg.) of caffeine. Three 
subjects were solicited for this study. The subject's 
average daily caffeine intake was not taken into consider-
ation. 
The test apparatus consisted of a light path (150 w., 
115 v.) to the subject's right eye with an optician's trial 
frame fixed to the subject's head. Each test session was 
the same. Fifteen minutes before entering the darkened test 
room, the subjects were given a placebo. After this period, 
34 
the subject entered the test site and was fitted with the 
optician's frame and allowed to adjust to the dark. Thresh-
old measurements were taken for 10 test-field areas. Then, 
the subject left for a one hour rest. Thirty minutes before 
reentering the darkroom the subject was given either a 1.5 
grain or 3.0 grain capsule of caffeine. 
The procedure described above was then repeated utiliz-
ing the remaining caffeine dose. Threshold luminance as a 
function of test radius was reported in log mL and threshold 
(in log mL) was plotted representing the respective caffeine 
doses. Results reported visual threshold luminescence 
significantly decreasing following ingestion of 1.5 grains 
and 3.0 grains of caffeine. These findings led the authors 
to intimate that caffeine causes the "on" visual pathways to 
become more sensitive to light and that decreases in the 
threshold corresponds to increases in the caffeine dose. 
Flicker fusion frequency was examined in a review by 
Simonsons and Brozek (1952) conducted in the early 1950's. 
This investigation described the evolution of the flicker 
fusion response in man originating from the belief that 
flicker fusion frequency was a retinal function to a broader 
application incorporating cortical involvement. 
Roback, Krasno, and Ivy (1952) conducted a study which 
addressed the effect of caffeine (30 mg.) on flicker fusion 
threshold. Caffeine, although a central nervous system 
stimulant, depressed flicker fusion frequency. This study 
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explored the effects of analeptic drugs on the effect of 
seconal and antihistamines to indicate various depressing 
and stimulating influences on the central nervous system 
with particular interest on visual mechanisms. There were 5 
experimental groups receiving caffeine alone or in combina-
tion with other drugs. Subjects in each group ranged in 
number from 10 to 30. Subjects were seated 5 feet from the 
"flicker photometer" to enable the flicker to fall correctly 
on the fovea centralis. Other sources of light were permit-
ted as long as the light source was not directed at the 
subject's eyes. The operator started the flickering light 
as 2900 flashes per minute (48.3 flashes per second) and 
reduced this speed at a constant rate until the subject 
reported flicker. After establishing a base line (3 identi-
cal rate times reported consecutively) the test drugs were 
given. Flicker fusion threshold was then measured every 15 
to 30 minutes for the next 2 to 3 hours depending on the 
group. T-tests revealed that caffeine alone, despite being 
a central nervous system stimulant, depressed flicker fusion 
frequency. 
King and Henry (1992) employed caffeine as a control in 
studying the effects of neuroleptic cognitive psychomotor 
function in healthy subjects. Critical flicker fusion 
threshold (CFFT) was used as one of the assessments. Twenty 
subjects were given single doses of caffeine (400 mg.) along 
with placebo and other drugs weekly in a double-blind, 
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randomized order. Volunteers were asked to abstain from 
caffeine for 12 hours before each test. CFFT was measured 
using the Leeds Psychomotor Tester and was reported as the 
mean of six runs, three with ascending and three with de-
scending flicker frequency. Tests were repeated at 1, 2, 3, 
6 and 24 hours. A principal component factor analysis 
revealed that caffeine (400 mg.) appeared to significantly 
impair CFFT at one hour (p<0.05). 
Kelly and Wilson (1978) examined human flicker sensi-
tivity exclusive from drug interactions from a mathematical 
perspective utilizing algebraic equations and progressions 
to address the question of whether flicker fusion discrimi-
nation was controlled by retinal mechanisms or higher visual 
centers. Results supported the hypothesis that flicker 
thresholds at high flicker frequencies are actually filtered 
by retinal units and then relayed to the rest of the visual 
system which could explain any delay or decrease in response 
time. 
Kerr, Sherwood, and Hindmarch (1991) examined the ef-
fects of social drugs on psychomotor performance. One of 
the assessment techniques utilized in assessing the effects 
of caffeine was critical flicker fusion. Ten subjects 
participated in this study. Subjects with required to 
discriminate flicker fusion in a set of four light emitting 
diodes held in foveal fixation at 1 meter (almost 3 feet). 
Individual thresholds were determined by eliciting responses 
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on three ascending and three descending scales. Average 
daily caffeine intake was not reported nor were requirements 
for abstinence from caffeine prior to testing reported. The 
findings of a one way repeated measures analysis of variance 
(ANOVA) support caffeine (250 mg.) acting as a central 
nervous system stimulant independent of fatigue. In addi-
tion, there was no significant fluctuations in central 
nervous system arousal as measured by critical flicker 
fusion following drug ingestion. As a result, these re-
searchers go on to postulate that caffeine may have a 
greater effect on information processing. 
The effects of caffeine on repetition blindness is the 
third visual measurement that was_ addressed in the current 
study. Early studies exploring perceptual processing led to 
utilizing repetition blindness as one of the measurement 
techniques. Logsdon, Hochhaus, Williams, Rundell, and 
Maxwell (1984) examined the effects of secobarbital on 
perceptual processing (specifically choice reaction time). 
Secobarbital, a central nervous system depressant with 
sedative and hypnotic qualities, was found to adversely 
effect perceptual processing. Later, Marohn and Hochhaus 
(1988) utilized repetition blindness in accessing relative 
perceptual fluency and found that semantic priming (priming 
word paired with a related word) increases stimulus duration 
and repeated priming (priming word paired with itself) 
decreased stimulus duration. Semantic priming apparently 
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increased perceptual fluency. Further, Hochhaus and Mihura 
(1993) explored word frequency effects on repetition blind-
ness and found that frequency effects interact with repeti-
tion blindness effects in a way that limits repetition 
blindness to either high frequency words or rare words made 
more familiar by pretraining. 
No studies exist that examine caffeine's effect on 
repetition blindness. Examining the effects of caffeine (a 
stimulant) on repetition blindness would appear to be a 
logical step, however, since secobarbital (a depressant) 
negatively effected perception (Logsdon et al., 1984). If 
secobarbital negatively effects perception, caffeine could 
theoretically improve it. 
Summary 
The neurological effects of caffeine have been exam-
ined. At the cellular level, caffeine has been hypothesized 
to effect four areas: intracellular mobilization of calci-
um, inhibition of phosphodiesterase, antagonism of adenosine 
receptor sites, and interactions with benzodiazepine binding 
sites. Of these four potential effects, antagonism of 
adenosine receptor sites appears to be the theory most 
commonly accepted. From a more broad perspective, caffeine 
has been linked to increased release of neurotransmitters 
and a possible decrease in cerebral blood flow which have 
implications on substrate utilization in the central nervous 
system. These plausible events, combined with the impulse 
conductivity that exists among the central, peripheral, 
autonomic nervous systems, may very well play an important 
role in regulating metabolism and ultimately behavior and 
performance. 
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Potential neuromuscular effects of caffeine include a 
decrease in the muscle fiber's excitation threshold, an 
increase in the length of contraction, and changes in sub-
strate metabolism. These events seem to evolve from three 
possible mechanisms: increased affinity of myofilaments for 
calcium and/or increased calcium release from the sarco-
plasmic reticulum; changes in cellular activity due to an 
increase in cAMP in skeletal muscle tissue; and inhibition 
of adenosine receptors sites in the central nervous system. 
This last theory, inhibition of adenosine receptors, appears 
to be the hypothesis most authorities prefer to explain the 
neuromuscular effects of caffeine. The propensity for 
making this choice is most understandable due to caffeine's 
reported inhibition of adenosine receptor sites and the 
relationship between the central and peripheral nervous 
systems. 
The influence of caffeine on vision is examined from 
two perspectives: (1) effects on the structural components 
of the eye itself and; (2) from the perspective of visual 
performance. From a structural standpoint, caffeine has 
reportedly resulted in a decrease in retinal blood flow 
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while increasing diastolic pressure. However, caffeine had 
no clinically significant effect on intraocular pressure. 
studies addressing caffeine's effects on visual performance 
examined various parameters and provided, in many cases, 
conflicting results. Caffeine's reported effects included 
both reductions and improvements of visual reaction time. 
Similarly, caffeine facilitated and impaired perceptual 
restructuring tasks. Certain parameters of selected visual 
processing were improved following caffeine ingestion as did 
visual tracking. However, decreases in response times were 
also reported. · studies examining caffeine's effect on 
visual vigilance resulted in both increases and decreases. 
And, the effect of caffeine on information processing of 
fatigued subjects were examined; reaction time decreased 
with results being effected by the fatigued state of the 
subject. 
The current study was interested in the effects of 
caffeine on visual performance utilizing three test proto-
cols: luminescent threshold comparisons, flicker fusion 
discrimination, and repetition blindness. Previous studies 
testing luminescent threshold report that caffeine may 
reduce contrast threshold and, in some cases, erase enhance-
ment effects. Studies examining the effect of caffeine on 
flicker fusion report conflicting results. Findings include 
a decrease in flicker fusion frequency (Roback et al., 1952) 
and an impairment of critical flicker fusion threshold (King 
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& Henry, 1992). One study (Kelly & Wilson, 1978) explains 
these decreases in flicker fusion frequency mathematically 
as occurring due to a delay in stimuli transfer from retinal 
units to higher visual centers. However, another study re-
ports no significant fluctuations central nervous system 
arousal evidenced by a lack of a significant change in 
critical flicker fusion threshold (Kerr et al., 1991). As 
for the effects of caffeine on repetition blindness, no 
studies were found. However, examination of the effects of 
this stimulant on repetition blindness would appear called 
for in light of the findings of previous works examining 
perception. 
Further caffeine research, particularly caffeine's 
effect on luminescent threshold comparisons, flicker fusion 
discrimination, and repetition blindness, needs to be con-
ducted. This call for further research is due to the uncer-
tainty surrounding the results of many such studies. This 
fact, combined with conflicting outcomes and a lack of data, 
demands subsequent examination. From a practical viewpoint, 
additional information concerning the effect of caffeine on 
vision could prove beneficial for those occupations relying 
on sight (e.g., air traffic controllers, pilots, profession-
al athletes, computer programmers, and data entry). More-
over, visual effects of caffeine could also impact the 
general population's recreational and leisure pursuits. 
CHAPTER III 
METHODOLOGY 
Subjects 
Fifteen college age students enrolled in the 1996 
summer semester and fifteen college age students enrolled in 
the 1996 fall semester at Oklahoma State University were 
solicited for this study. These subjects represented a 
convenience sample based on availability. 
Each subject voluntarily read, signed and dated an in-
formed consent form approved by the Institutional Review 
Board at Oklahoma state University (Appendix A) which out-
lined the study's protocol, as well as, possible risks. 
This process occurred following a detailed verbal briefing 
outlining the scope of the study, purpose, procedures, and 
potential risks. In addition, the subject answered ques-
tions about their medical history, (Caffeine Research 
Questionnaire, Appendix B) describing physical conditions, 
medications, or disorders that may have proved problematic 
for the subject or hampered the study. This document 
(Caffeine Research Questionnaire, Appendix B) also included 
questions determining the subjects's caffeine consumption 
history and average daily intake. To inform participants, 
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as well as, facilitate the computation of caffeine intake, 
the subjects were also presented with a handout identifying 
the caffeine content of common beverages, foods, & medica-
tions (Appendix C). 
The principal investigator verbally screened any sub-
jects indicating elevated caffeine intake {>200 mg.) or 
preexisting physical conditions (e.g., heart problems, 
intestinal disorders, mental/emotional disorders, and high 
blood pressure) upon examining each subject's daily caffeine 
intake and medical history. Based on the responses given, 
subjects in question were either eliminated from the study 
or made fully aware of possible side-effects. Due to 
medical history findings (e.g., heart murmur and depression) 
and scheduling problems (e.g., test times conflicting with 
work or classes) seven of the thirty volunteers were either 
eliminated or were unable to participate in the study. 
Twenty-three subjects completed testing. All data, the 
informed consent form, medical history questionnaire, and 
all responses were held in strict confidence and filed with 
the principal investigator. 
Preliminary Procedures 
Testing was conducted in the Exercise Physiology Lab at 
Oklahoma State University. This location was chosen based 
on student accessibility, availability of adequate space, 
ability to provide semi-dark lighting, and relative freedom 
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from visual or auditory interference. On the test date, 
each subject was instructed to fast for five hours prior to 
testing. In the digestive process, food spends approximate-
ly 2 to 4 hours in the stomach (Clayman, 1989). By fasting 
for five hours, caffeine was absorbed more quickly and 
completely. Similarly, the subjects were directed to 
abstain from caffeine for forty-eight hours prior to testing 
to achieve a reduction in caffeine tolerance and to prevent 
any residual caffeine from interfering with the study. 
The test site was semi-dark with partitions separating 
the three test stations. Upon arrival, the subjects were 
seated and asked to respond to five questions related to 
food and caffeine consumption and the subject's general 
state of well being (e.g., presence of a hangover, lack of 
sleep, time of last meal, and time/form of last caffeine 
consumed) (Vital study Criteria on the Caffeine Research 
Questionnaire, Appendix B). Based on these responses, the 
subjects were given the opportunity to reschedule the test 
session. If rescheduling was not necessary, blood pressure 
and pulse readings were taken utilizing Lafayette model #UA-
701 digitized blood pressure meter and recorded on the 
Caffeine Research Questionnaire (Appendix B). This data was 
utilized to compare pre-test and post-test blood pressure 
and pulse measurements following caffeine ingestion. These 
procedures were taken to monitor the subject's health status 
and identify any adverse physiological reactions to caffeine 
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at which time medical assistance would have been provided. 
The subject's caffeine dosage was prepared by a local 
pharmacist based on the subject's weight as reported on the 
Caffeine Research Questionnaire (Appendix B). Two dosages 
of caffeine, 2.5 mg. per kg. bwt. and 5.0 mg. per kg. bwt., 
and one placebo was prepared for each subject. The caf-
feine, which was administered in capsule form, was Caffeine, 
USP, Anhydrous. Similarly, gelatin capsules filled with 
Sodium Bicarbonate represented the placebo. 
Equipment and Testing Procedure 
All tests, pre and post-tests, were repeated on three 
separate occasions during a three week period until all sub-
jects had been administered the three doses of caffeine. 
Pre-tests and post-tests began with the investigator reading 
the subject instructions related to each of the three visual 
tests (Appendix F). Pre-tests were followed by administra-
tion of one form of the treatment {placebo, 2.5 mg./kg. 
bwt., or 5.0 mg./kg. bwt. of caffeine) with 118 ml. of tap 
water. After completion of the pre-tests, subjects were 
then asked to maintain their fast and refrain from addition-
al caffeine consumption. After waiting at least one hour, 
but not more that three hours (caffeine's half-life), the 
post-tests were conducted following the same protocol 
described above. This weekly administration of placebo or 
caffeine was conducted randomly; neither the subjects nor 
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the technicians administering the tests were aware of the 
dosage. Since each subject was administered one of the 
three treatments (placebo, 2.5 mg./kg. bwt. caffeine, or 5.0 
mg./kg. caffeine) per week for a three week period, subjects 
served as their own control. Test results were recorded 
after each testing session (both pre and post) on a data 
sheet (Appendix E). 
The tests (pre and post) involved three modalities: 
luminescence threshold comparisons, flicker fusion discrimi-
nation, and repetition blindness. Luminescence threshold 
comparisons were measured by Lafayette model #14011 (1701), 
Light Discrimination Apparatus. According to Lafayette 
(1970), this model was designed to present two 1-3/8 in. 
light stimuli from a single common source, however, each 
stimuli could be independently varied in intensity by means 
of a precisely tapered aperture and finely calibrated scales 
on each side of the unit. The stimulus lamp was a 15 watts 
and 115 volts with a single contact candelabra base. Due to 
uncontrolled variables such as fluctuations in voltage, the 
absolute value of the stimulus could not be determined 
(Lafayette, 1970). However, relative differences between 
the two stimuli were reported to be highly reliable since a 
common light source was employed (Lafayette, 1970). 
Subjects were instructed to sit directly in front of 
the Light Discrimination Apparatus. The distance between 
the unit and the subject was the subject's arm distance to 
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allow for adjustment of the dominant hand's dial. Three 
trials were conducted during each test session with the sub-
ject trying to reproduce a predetermined light stimulus with 
their dominant hand. The standard that the subjects at-
tempted to reproduce included: 140 units, 290 units, and 
220 units. 
Flicker fusion discrimination was measured by Lafay-
ette model #58017, Visual Perception Control, which was 
designed specifically for this visual test. However, Lafay-
ette (1986) reported that the accuracy for this piece of 
equipment was "greater that 10%" and repeatability was 
"greater than 3%". Again, as with the Light Discrimination 
Apparatus, uncontrolled factors such as voltage fluctuation 
possibly served as a confounding variable (Lafayette, 1986). 
Subjects were seated directly in front of the apparatus 
and asked to focus their attention on the two flickering 
lights. Each test (pre and post) consisted of three trials 
with the researcher starting the test at 10 flickers per 
second followed by a gradual increase to a maximum of 50 
flickers per second. The subjects verbally indicated to the 
investigator the point when the flickering lights became one 
continuous light. 
The final test measured repetition blindness. This 
test was conducted by using a computerized program created 
to measure repetition blindness by Dr. Larry Hochhaus, 
professor of Psychology, Oklahoma State University. Each 
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subject completed 40 trials to allow for the accurate depic-
tion of repetition blindness while attempting to avoid the 
confounding effects of fatigue. The first eight trials were 
considered practice with the remaining thirty-two trials 
being recorded as correct and incorrect. Each trial con-
sisted of the subject viewing a "prime" word for 300 milli-
seconds (ms.) displayed two lines above a pair of arrows 
(---> <---) which marked the location of the "target" 
word. The "target" was then viewed for 17 ms. The prime 
word was a capitalized four letter word while the target 
word could be either the prime word repeated or a different 
capitalized four letter word. The target word was immedi-
ately replaced by a 500 ms. row of six ampersands (&&&&&&). 
The subject was directed to repeat the target word to enable 
the investigator to record each response on a weekly pre/po-
st test repetition blindness response sheet (Appendix D). 
Post Procedure 
Subjects were encouraged to consume a meal following 
the post-test. Foods high in carbohydrates and low in 
fats/grease were suggested to decrease the potential for 
stomach upset and nausea. Subjects were also directed and 
encouraged to inform the principal investigator of any ill 
feelings following the tests. Each testing session lasted 
approximately 1.5 hours. Therefore, the total time neces-
sary to complete all sessions was approximately 4.5 hours. 
Statistical Treatment 
This study utilized a within subject research design. 
Caffeine doses (2.5 mg./kg. bwt. or 5.0 mg./kg. bwt.) or 
placebo were administered randomly to all subjects using a 
double-blind format. Each subject served as their own 
control through implementation of a pre and post-test 
protocol. 
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The data was analyzed using 2 x 3 repeated measures 
analyses of variance (ANOVAs) to test for significance be-
tween pre-test and post-test responses on the three visual 
tests (luminescent threshold comparisons, flicker fusion 
discrimination, and repetition blindness). In analyzing 
flicker fusion discrimination and repetition blindness, 
difference between pre and post-test responses represented 
the dependent variable. In both cases, three levels of 
caffeine (O, 2.5, and 5.0 mg./kg. bwt.) and time of testing 
(pre and post) served as independent variables. In making 
luminescent threshold comparisons, three 2 x 3 repeated mea-
sures ANOVAs were utilized to determine significance between 
pre-test and post-test scores at the three different light 
intensity levels (140, 290 and 220 units). The difference 
between pre and post-test scores at these three light inten-
sity levels represented the dependent variable in each 
ANOVA. And, as with flicker fusion and repetition blind-
ness, caffeine (3 levels) and time of testing (pre and post) 
served as the independent variables. Newman-Keuls post hoc 
analyses were conducted based on the significant findings 
reported by the repeated measures ANOVAs. 
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CHAPTER IV 
RESULTS AND DISCUSSION 
Results 
This investigation examined the effects of three 
treatment levels of caffeine on three visual tests. Partic-
ipant characteristics were initially analyzed utilizing 
descriptive statistics. The descriptive statistics in-
cluded: age, gender, weight, height, and average daily 
caffeine consumption. 
The mean age of the subjects was 23.39 (+ 5.31) years. 
The standard error (or standard deviation of the sampling 
distribution of means) of ages was 1.12 years. Since most 
of the scores were clustered at the lower end of the distri-
bution, the distribution could be described as being posi-
tively skewed with skewness reported at 2.70 (Table II). 
This study collected data from 23 subjects. The sub-
ject pool was comprised of 14 women and 9 men (Table III). 
The subjects• mean weight was 159.91 (± 50.19) pounds. 
Standard error of the reported weights was 10.46 pounds. A 
greater number of subjects' weights were located at the 
lower end of the range (positively skewed) with skewness 
reported at 1.09 (Table IV). 
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TABLE II 
FREQUENCY DISTRIBUTION OF SUBJECTS' AGES 
Years Frequency Percent 
19 3 13.0 
20 3 13.0 
21 2 8.7 
22 6 26.1 
23 3 13.0 
24 2 8.7 
27 2 8.7 
33 1 4.3 
43 L 4.3 
Total 23 100.0 
Mean 23.39 Std. Error 1.11 
Variance 28.20 Skewness 2.70 
Mean 
Variance 
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TABLE III 
FREQUENCY DISTRIBUTION OF SUBJECTS' GENDERS 
Gender Frequency Percent 
Male 9 39.1 
Female _l.L 60.9 
Total 23 100.0 
1. 61 Std. Error .10 
.25 Skewness -.48 
Mean 
Variance 
TABLE IV 
FREQUENCY DISTRIBUTION OF SUBJECTS' WEIGHTS 
Pounds 
105 
108 
112 
122 
124 
125 
130 
135 
140 
151 
156 
160 
163 
165 
205 
215 
235 
250 
285 
Total 
159.91 
2519.04 
Frequency 
1 
1 
2 
1 
1 
2 
1 
1 
2 
1 
1 
1 
1 
1 
1 
2 
1 
1 
__ 1_ 
23 
Percent 
4.3 
4.3 
8.7 
4.3 
4.3 
8.7 
4.3 
4.3 
8.7 
4.3 
4.3 
4.3 
4.3 
4.3 
4.3 
8.7 
4.3 
4.3 
4.3 
100.0 
Std. Error 
Skewness 
10.46 
1.10 
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The mean height of the subjects was 170.12 (± 9.49) 
centimeters. The standard error reported was 1.98 centime-
ters. Height was more evenly dispersed in the subject pool 
when compared to the other descriptive data. However, the 
distribution was slightly positively skewed (.09) since more 
of the scores were located toward the lower end of the range 
(Table V). 
Mean caffeine consumption per day for this group of 
subjects was 130.8 (± 96.12) milligrams (approximately 1 cup 
of coffee or 2 sodas). The standard error was reported at 
20.05 milligrams which represented the computed difference 
between caffeine actually consumed verses caffeine reported. 
The scores were positively skewed since most of the students 
had low (below the 200 mg. average intake per day) caffeine 
intake (Table VI). 
This investigation involved examining the effects of 
three treatment levels of caffeine on three separate tests 
of vision. Five hypotheses were tested to determine if 
there were significant differences in visual performance on 
three visual tests (luminescent threshold comparisons, 
flicker fusion discrimination, and repetition blindness) 
following ingestion of three doses of caffeine (0, 2.5, and 
5.0 mg./kg. bwt.). Five 2 x 3 repeated measures analysis of 
variance (ANOVA) were used to analyze the treatment effect 
of the three levels of caffeine on the three visual tests. 
Newman-Keuls post hoc analyses were conducted on significant 
Mean 
Variance 
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TABLE V 
FREQUENCY DISTRIBUTION OF SUBJECTS' HEIGHTS 
Inches Frequency Percent 
60 1 4.3 
62 2 8.7 
63 1 4.3 
64 3 13.0 
65 1 4.3 
66 4 17.4 
67 1 4.3 
68 2 8.7 
69 2 8.7 
71 3 13.0 
72 2 8.7 
74 _1_ 4.3 
Total 23 100.0 
66.96 Std. Error .78 
13.99 Skewness .09 
57 
TABLE VI 
FREQUENCY DISTRIBUTION OF SUBJECTS' DAILY 
CAFFEINE CONSUMPTION 
MSh Freguency Percent 
.o 2 8.7 
41. 6 4 17.4 
62.4 2 8.7 
83.2 1 4.3 
91.2 1 4.3 
101.6 1 4.3 
107.2 1 4.3 
124.8 1 4.3 
130.0 1 4.3 
145.6 1 4.3 
177.4 1 4.3 
198.2 1 4.3 
198.4 1 4.3 
208.0 1 4.3 
223.2 1 4.3 
293.2 1 4.3 
300.0 1 4.3 
335.2 __ 1_ 4.3 
Total 23 100.0 't J 
Mean 130.80 Std. Error 20.05 
Variance 9248.67 Skewness .64 
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ANOVA results. 
Hypothesis I stated that the pre to post-test differ-
ence score for luminescent threshold comparisons would 
remain consistent across the three treatment levels (place-
bo, 2.5 mg./kg. bwt. caffeine, and 5.0 mg./kg. bwt. caf-
feine) at the "low" luminescence setting (140 units). The 
repeated measures ANOVA revealed significant findings (F = 
3.619; p < .05) (Appendix G). This hypothesis was rejected. 
There were differences in responses to "low" luminescence at 
the various caffeine dosages. A Newman-Keuls post hoc 
analysis (p < .05) yielded significant differences across 
the 2.5 mg./kg. bwt. and 5.0 mg./kg. bwt. caffeine dosages 
at "low" light intensity (Figure 2). See means and probabil-
ities for the Newman-Keuls post hoc analysis in Appendix H. 
Hypothesis II stated that the pre to post-test differ-
ence score for luminescent threshold comparisons would 
remain consistent across the three treatment levels (place-
bo, 2.5 mg./kg. bwt. caffeine, and 5.0 mg./kg. bwt. caf-
feine) at "moderate" luminescence (220 units). The repeated 
measures ANOVA revealed a statistically significant differ-
ence (F = 4.362; p < .05) in pre-test and post-test perfor-
mance under different caffeine dosages (Appendix G). The 
null hypothesis was rejected. Further examination through 
the use of the Newman-Keuls post hoc analysis revealed that 
the difference was significant (p < .OS) in responses at 
moderate luminescence across 2.5 mg./kg. bwt. and 5.0 
30 
--·-- ::C ±Std. Dev. 
. ~ . ±Std. Err. 
c Mean 
------·-·----·--·-· 
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* Significant at p<.05. 
Figure 2. Group comparisons at low luminescence. 
mg./kg. bwt. of caffeine and across the placebo and 5.0 
mg./kg. bwt. of caffeine (Figure 3 and Appendix H). 
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Hypothesis III stated that the pre to post-test differ-
ence score for luminescent threshold comparisons would 
remain consistent across the three treatment levels (place-
bo, 2.5 mg./kg. bwt. caffeine, and 5.0 mg./kg. bwt. caf-
feine) at the "high" luminescence setting (290 units). The 
2 x 3 repeated measures ANOVA conducted on data at the 
"high" luminescence setting (290 units) revealed no signifi-
cant differences (F = 1.864; p > .05) (Figure 4, Appendix G, 
and Appendix H). The null hypothesis was not rejected. 
With luminescent threshold at the "high" setting, there 
appeared to be no evidence of pre to post-test pattern 
differences among the treatment levels. 
Hypothesis IV stated that there would be no difference 
between pre-test and post-test flicker fusion responses 
after consumption of placebo, 2.5 mg./kg. bwt., and 5.0 
mg./kg. bwt. caffeine. The repeated measures ANOVA revealed 
that there was a significant effect (F = 7.236; p < .05) 
(Appendix G). This hypothesis was rejected. Further appli-
cation of a Newman-Keuls test of this specific hypothesis 
revealed a significant effect (p < .05) only between the pre 
and post-test at 2.5 mg./kg. bwt. caffeine (Figure 5 and 
Appendix H) • 
Hypothesis V stated that there would be no difference 
between pre-test and post-test repetition blindness respons-
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Figure 3. Group comparisons at moderate luminescence. 
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Placebo Caff 2.5 mg. Caff 5.0 mg. 
Figure 4. Group comparisons at high luminescence. 
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Figure 5. Group flicker fusion comparisons 
at 2.5 mg. caffeine. 
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es after consumption of placebo, 2.5 mg./kg. bwt., and 5.0 
mg./kg. bwt. caffeine. This hypothesis was also rejected. 
Statistical significance was provided by the repeated mea-
sures ANOVA {F = 3.469; p < .05) (Appendix G.) Further 
Newman-Keuls test revealed significance (p < .05) in repeti-
tion blindness scores only between the pre and post-tests at 
the 2.5 mg./kg. bwt. caffeine dose level {Figure 6 and 
Appendix H). 
Discussion of Results 
This study examined the effects of three doses of caf-
feine on three visual tests. The findings of the analyses 
will be discussed to clarify results. The current study 
will also be interpreted with respect to previous studies in 
order to identify additions to the existing body of knowl-
edge, generate ideas for future research in this field, and 
suggest adaptations in protocol for further studies. 
Analytical Findings 
Repeated measures analyses of variance (ANOVAs} were 
the statistical analyses utilized in this study. This type 
of analysis is commonly used by researchers examining caf-
feine's effects on various physical parameters (Jacobson & 
Edgley, 1987; Jacobson & Thurman-Lacey, 1992; Jacobson, 
Webster, Claypool, & Hunt, 1992; Jacobson & Winter-Roberts, 
1991; Kerr et al., 1991). Five 2 x 3 repeated measures 
e 
e 
... 
w 
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* Significant at p<.05. 
Figure 6. Group repetition blindness comparisons 
at 2.5 mg. caffeine. 
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ANOVAs were conducted to examine the effects of three dosag-
es of caffeine (O mg./kg. bwt.; 2.5 mg./kg. bwt.; and 5.0 
mg./kg. bwt.) on three visual tests (luminescent threshold 
comparisons, flicker fusion discrimination, and repetition 
blindness). Of these five ANOVAs, only one (luminescent 
threshold comparisons at high luminescence) did not result 
in significance. Newman-Keuls post hoc analyses were con-
ducted on the four significant ANOVA results. (ANOVA summa-
ry tables are located in Appendix G and Newman-Keuls results 
are found in Appendix H.) 
Luminescent Threshold Comparisons. Post hoc analysis 
of low luminescence data revealed significance between the 
subject's pre and post-test gain score responses at the 2.5 
mg./kg. bwt. and 5.0 mg./kg. bwt. caffeine doses. At this 
low light intensity, luminescent threshold comparisons 
varied a significant amount when mean responses at 2.5 
mg./kg. bwt. caffeine (mean= 16.70 ± 15.39} were compared 
to mean responses at the 5.0 mg./kg. bwt. caffeine dose 
(mean= 9.09 ± 6.76). More divergent scores occurred after 
ingestion of 2.5 mg./kg. bwt. caffeine compared to the 5.0 
mg./kg. bwt. dose. Similarly, a Newman-Keuls post hoc 
analysis was conducted on moderate luminescence data and two 
areas of significance were reported. Significance was found 
across the 2.5 and 5.0 mg./kg. caffeine doses and across the 
placebo and the 5.0 mg./kg. bwt. dose of caffeine. Lumines-
cent threshold comparisons varied significantly at moderate 
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luminescence in response to 5.0 mg./kg. bwt. caffeine (mean 
= 22.52 ± 22.83) compared to both the 2.5 mg./kg. bwt. dose 
(mean= 11.91 + 7.47) and placebo (mean= 10.61 + 8.39). 
More divergent pre to post-test scores occurred following 
ingestion of 5.0 mg./kg. bwt. caffeine dose compared to 
those reported following ingestion of placebo or the 2.5 
mg./kg. bwt. dose. The repeated measures ANOVA at high 
luminescence reported no significant effects between the 
treatments and vision. 
Flicker Fusion Discrimination. The Newman-Keuls post 
hoc analysis indicated significance between pre-tests and 
post-tests at 2.5 mg./kg. bwt. caffeine for flicker fusion 
discrimination. Flicker fusion was significantly postponed 
after consumption of 2.5 mg./kg. bwt. caffeine (pre-test 
mean= 38.74 + 6.74; post-test mean= 41.56 + 4.47). Sub-
jects were able to discriminate between flicker and fusion 
of the stimuli at greater flickers per second. 
No significant findings between pre and post test 
responses at the other two levels of caffeine were reported 
by the post hoc analysis for flicker fusion discrimination. 
No significance was identified between pre and post-test 
responses after administration of the placebo. These 
findings were anticipated since no caffeine was adminis-
tered. However, no significance was also reported between 
pre and post-test responses after consuming the 5.0 mg./kg. 
caffeine dose. Since flicker fusion was postponed with the 
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2.5 mg./kg. bwt. dose, further delay of flicker fusion would 
have conceivably been expected after consuming the higher 
caffeine dose. 
Repetition Blindness. Improvement in performance was 
described when the final post hoc analysis revealed repeti-
tion blindness decreased from pre to post-test following 2.5 
mg./kg. bwt. caffeine ingestion (pre-test mean= 5.13 ± 
9.84; post-test mean= 1.83 ± 4.88). Subjects were able to 
identify the target word more frequently following consump-
tion of 2.5 mg./kg. bwt. of caffeine compared to pre-test 
results. 
No significant findings were identified by the Newman-
Keuls post hoc analysis conducted on pre to post-test 
repetition blindness responses after consumption of the 
placebo or the 5.0 mg./kg. bwt. caffeine dose. As with 
flicker fusion discrimination, the lack of significant 
findings was expected after administration of the placebo. 
No stimulant (caffeine) was ingested. However, it was quite 
surprising that the 5.0 mg./kg. bwt. dose did not further 
decrease repetition blindness thereby increasing performance 
an even greater degree compared to the effects of the 2.5 
mg./kg. bwt. dose. 
Summary. Dose related responses appear to be a common 
theme throughout these findings. In the luminescent thresh-
old comparisons, significant differences in pre to post-test 
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scores were identified across the 2.5 mg./kg. bwt. caffeine 
dose and the 5.0 mg./kg. bwt. dose at low luminescence. The 
pre to post-test differences at 2.5 mg./kg. bwt. caffeine 
varied to a greater degree than the results at the higher 
dose (5.0 mg./kg. bwt.). Conversely, at moderate lumines-
cence, the difference in test scores at 5.0 mg./kg. bwt. 
caffeine varied more than both the 2.5 mg./kg. bwt. caffeine 
and placebo scores. And for flicker fusion comparisons and 
repetition blindness, the 2.5 mg./kg. bwt. caffeine dose 
produced a greater divergence in performance compared to 
both the placebo and 5.0 mg./kg. bwt. dose. These results 
tend to imply dose related responses (Eveden et al., 1993; 
Jacobson & Edgley, 1987; Jacobson & Thurman-Lacey, 1992; 
Jacobson, Winter-Roberts, & Gemmell, 1991; Loke & Meliska, 
1984; Fine et al., 1994). 
The one exception to the idea that caffeine's effects 
are dose related is that no significant differences between 
pre and post-test scores were reported in luminescent 
threshold comparisons at high luminescence. However, 
another pattern appears to have developed between caffeine 
and the various light intensities. The eye seems to require 
higher levels of caffeine to produce significant responses 
to the stimulus as the stimulus increases in intensity. At 
low luminescence, the 2.5 mg./kg. bwt. caffeine dose pro-
duced greater fluctuations in pre to post-test scores. 
Significant fluctuations between scores also occurred at 
moderate luminescence; however, a higher caffeine dosage 
(5.0 mg./kg. bwt.) was required. No significance was 
reported at high luminescence. If this pattern was to 
continue, a higher level of caffeine (7.5 mg./kg. bwt.) 
could elicit significant results. 
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The discussion of results is somewhat complicated due 
to differences in the caffeine status of the subjects. The 
average caffeine intake reported by subjects in this study 
ranged from o mg. to 335.2 mg. per day with 130.8 mg. repre-
senting the subjects• mean daily intake (Table VI). Despite 
the fact that subjects were instructed to abstain from food 
(for five hours) and caffeine (for forty-eight hours) prior 
to testing in an attempt to diminish individual differences, 
caffeine tolerance could have affected the subjects with 
higher daily caffeine intake (5 subjects consumed >200 
mg./day) and may have altered or masked results (Sawynok, 
1995). On the other hand, the five subjects with higher 
daily intake who did follow directions and abstained from 
caffeine could have experienced caffeine withdrawal which 
may have adversely affected performance (Brecher, 1972). 
Even though the majority (18 subjects) consumed less than 
the average daily intake of 200 mg. and 10 subjects could be 
classified as caffeine naive (<100 mg.), the results may be 
slightly skewed due to the above average caffeine intake of 
a few of the subjects. 
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Comparison of the Current Study with Previous studies 
The current study was conducted to contribute to the 
existing body of knowledge that exists concerning the ef-
fects of caffeine on vision. To make this contribution, 
this study must be compared to previous studies. However, 
differences in statistical analyses and experimental proto-
cols complicate these comparisons. To simplify matters, the 
current study's protocol and statistical analyses examining 
caffeine's effects on three visual tests (luminescent 
threshold comparisons, flicker fusion discrimination, and 
repetition blindness) will be compared to those of previous 
research. In addition, current findings will be compared 
and contrasted to those of previous studies. 
The current study's protocol required twenty-three 
subjects to abstain from caffeine for forty-eight hours and 
food for five hours. Each test session (both pre and post-
tests) began in a semi-dark room with the subjects complet-
ing a pre-test screening followed by three visual tests. 
Luminescent threshold comparisons and flicker fusion dis-
crimination were conducted separately by utilizing two 
apparatus designed by Lafayette. Repetition blindness was 
examined through the use of a computerized program. Follow-
ing the pre-tests, either one dose of caffeine (2.5 mg/kg. 
bwt. or 5.0 mg./kg. bwt.) or the placebo was administered to 
the subjects. The post-test occurred at least one hour 
after treatment. This process was repeated on three sepa-
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rate occasions during a three week period until all subjects 
had been administered the three doses of caffeine. Data was 
analyzed using 2 x 3 repeated measures ANOVAs with signifi-
cant findings being further analyzed by Newman-Keuls post 
hoc analyses. 
Luminescent Threshold Comparisons. Luminescent thresh-
old comparisons have previously been examined using various 
apparatus, protocols, and statistical analyses. Kleman et 
al. (1961) examined the effects of caffeine on "foveal 
simultaneous contrast" by utilizing a small circular test 
field surrounded by an inducing annulus. The test apparatus 
separated the right and left visual pathways. A different 
visual pattern and a separate light source (100 w.) was 
provided for each eye. The study was conducted utilizing 
three subjects (low to moderate caffeine users) who were 
instructed to abstain from caffeine for 24 hours. Testing 
was conducted on two separate days. on each day, subjects 
were first administered a placebo and tested approximately 
30 minutes later. This process was then repeated with 3 
grains (194.4 mg.} of caffeine serving as the treatment. 
Results were reported in log millilamberts (log mL} as a 
function of the inducing field luminance and plotted as a 
function of the log luminance. 
Diamond and Cole (1970} examined visual threshold as a 
function of test area and caffeine administration. Thresh-
old luminance of a circle was measured in relation to its' 
73 
area before and after ingestion of 3 different doses of caf-
feine (placebo, 1.5 grains or 97.2 mg., and 3.0 grains or 
194.4 mg.). The test apparatus consisted of a light path 
(150 w.) to the subject's right eye. Three subjects were 
solicited for this study without considering average daily 
caffeine intake. Each test session began with the placebo 
being administered to the subjects. After approximately 30 
minutes, threshold measurements were taken for 10 test-field 
areas. This procedure was repeated in one hour with one of 
the caffeine doses (randomly administered) instead of the 
placebo. The remaining dose of caffeine was administered 
when this protocol was repeated a third time. Threshold 
luminance as a function of test radius was reported in log 
mL and threshold (in log mL) was plotted representing the 
respective caffeine doses. 
Comparing these research studies designed to measure 
luminescent threshold with the current study is quite diffi-
cult due to inherent differences. The differences between 
the previous studies and the current study include: statis-
tical analyses, test apparatus (e.g., monocular vs. binocu-
lar, distance of subjects from apparatus, and intensity of 
light source), amount of caffeine administered (97.2 mg. and 
194.4 mg. vs. 2.5 mg./kg. bwt. and 5.0 mg./kg. bwt.), number 
of subjects, time between caffeine ingestion and post-test, 
and pre-test caffeine status of subjects. Despite these 
differences, however, there are some similarities between 
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the previous studies and the current study. Klemen et al. 
(1961) tested subjects that were classified as moderate to 
low caffeine users which is similar to the current study. 
And, Diamond and Cole (1970) administered a placebo, 1.5 
grains (97.2 mg.) of caffeine, and 3.0 grains (194.4 mg.) of 
caffeine to their subjects. (Even though there were three 
levels of treatment, the dosages were generally below the 
amount of caffeine administered in the current study). 
The previous studies found that caffeine did effect the 
subject's ability to discriminate between light intensity 
levels despite differences in apparatus and protocols. In 
the case of Diamond and Cole (1970), the overall decrease in 
luminescence grew more pronounced as the caffeine dosage in-
creased from 1.5 grains (97.2 mg.) to 3.0 grains (194.4 
mg.). These findings hint of a dose related response al-
though a blanket dose of caffeine does not accommodate 
differences in the weights of subjects compared to caffeine 
administered according to body weight. One problem these 
studies have when applying currently held beliefs about 
caffeine is that both studies tested luminescent threshold 
less than one hour after caffeine ingestion. As reported by 
Axelrod & Riechenthal (1953), caffeine levels peak in the 
blood stream approximately one hour after ingestion. Both 
studies tested luminescent threshold before maximum caffeine 
levels were achieved in the subject's bloodstreams. 
The present study's results do parallel previous find-
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ings at low luminescence with luminescent threshold compari-
sons varying to a greater degree following ingestion of 2.5 
mg./kg. bwt. of caffeine compared to less variation at the 
5.0 mg./kg. dose. The higher dose (5.0 mg./kg. bwt.), at 
moderate luminescence, resulted in greater pre to post-test 
score variation compared to comparisons made at the lower 
dose (2.5 mg./kg. bwt.) or the placebo. However, unlike 
previous studies, no significance was found at high lumines-
cence. 
Caution should be used when comparing the current 
results with those of previous studies due to differences 
that include caffeine dosage, light intensity, and failure 
to test one hour after caffeine ingestion. However, the 
current low and moderate luminescence results do seem to 
infer, as did Diamond and Cole (1970), that luminescent 
threshold has a dose related response to caffeine when 
tested at different intensities. There was a significant 
variation in luminescent threshold comparisons at low lumi-
nescence at 2.5 mg./kg. bwt. caffeine compared to 5.0 mg./-
kg. bwt. caffeine in the current study. Similarly, at 
moderate luminescence, significant variations in luminescent 
threshold comparisons were also reported. However, at 
moderate luminescence, comparisons of pre to post-test 
differences varied to a greater degree after ingestion of 
5.0 mg./kg. bwt. caffeine when compared to placebo or 2.5 
mg./kg. bwt. caffeine. Depending on luminescence (low or 
moderate), the caffeine dose seems to have significant 
effects. 
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The lack of significance at high luminescence was 
somewhat unexpected considering the results of the low and 
moderate luminescence tests. Higher intensities of light 
may deter the effects of the two doses of caffeine utilized 
in this study or the eye's sensitivity to light may be more 
pronounced in response to such an intense stimuli (e.g., the 
eye may be more sensitive to light at high luminescence 
preventing caffeine from eliciting a change in luminescent 
threshold comparisons). In either case, if the current 
trend was to continue, a higher caffeine dose (e.g., 7.5 
mg./kg. bwt.) might elicit a wider range of pre to post-test 
response differences at high luminescence. 
Flicker Fusion Discrimination. studies examining 
flicker fusion discrimination have varied over the years 
with respect to test apparatus, protocol, statistical 
analyses, and findings. In the current study, one of the 
three dosages of caffeine significantly affected flicker 
fusion. (The pre-test/post-test mean difference was signif-
icant at the 2.5 mg./kg. bwt. caffeine dose.) However, when 
comparing this study with earlier studies, the latter varied 
with respect to apparatus and protocol in addition to 
reporting conflicting results. 
Roback et al. (1952) examined the effects of caffeine 
on flicker fusion threshold utilizing a "flicker photome-
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ter". In this study, caffeine was used as a control. Five 
experimental groups, each comprised of 10 to 30 subjects, 
received caffeine (30 mg.) alone or in combination with 
other drugs. After establishing a base line or norm, the 
drugs (caffeine) was administered. Flicker fusion threshold 
was then measured every 15 to 30 minutes for the next 2 to 3 
hours depending on the group. T-tests revealed that caf-
feine alone, despite being a central nervous system stimu-
lant, depressed flicker fusion frequency. 
King and Henry (1992) also employed caffeine as a 
control in studying the effects of neuroleptics on cognitive 
psychomotor function in healthy subjects. Critical flicker 
fusion threshold (CFFT) was used as one of the assessments. 
Twenty subjects were given single doses of caffeine (400 
mg.), along with other drugs, weekly in a randomized order. 
Subjects were asked to abstain from caffeine for 12 hours 
before each test. CFFT was measured using the Leeds Psycho-
motor Tester. Tests were repeated at 1, 2, 3, 6, and 24 
hour intervals. A principal component factor analysis 
revealed that caffeine (400 mg.) appeared to significantly 
impair CFFT at one hour (p<0.05). 
Kerr et al. (1991) examined the effects of social drugs 
on psychomotor performance. One of the assessment tech-
niques utilized in examining the effects of caffeine was 
critical flicker fusion. Ten subjects participated in this 
study. Subjects were required to discriminate flicker 
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fusion in a set of four light emitting diodes held in foveal 
fixation at 1 m. (almost 3 ft.). Average daily caffeine 
intake was not reported nor were requirements for abstinence 
from caffeine prior to testing reported. The findings of a 
one way repeated measures ANOVA support caffeine (250 mg.) 
acting as a central nervous system stimulant independent of 
fatigue. In addition, there was no significant fluctuations 
in central nervous system arousal as measured by critical 
flicker fusion following drug ingestion. 
The results of the current study conflict with the 
findings of the three previous studies. Considering the 
current ANOVA and post hoc results, the 2.5 mg./kg. bwt. 
dose of caffeine increased flicker fusion discrimination 
between the pre and post-test which is contrary to the 
studies just cited. As with luminescent threshold compari-
sons, differences between the studies make it difficult to 
compare the current study with these three studies. 
The study conducted by Kerr et al. (1991) was the only 
one of the three previous studies to use a repeated measures 
ANOVA to analyze data. All three of the apparatus in the 
previous studies varied from each other and from the appara-
tus used in the current study. Likewise, the time of test-
ing following caffeine ingestion also varied. Roback et al. 
(1952) measured flicker fusion threshold every 15 to 30 min-
utes for 2 to 3 hours after caffeine ingestion. King and 
Henry (1992) determined critical flicker fusion threshold 1, 
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2, 3, 6 and 24 hours after caffeine ingestion. And, Kerr et 
al. (1991) examined subjects half an hour after caffeine 
ingestion. Only the studies conducted by Roback et al. 
(1952) and King and Henry (1992) allowed enough time after 
ingestion for peak caffeine levels to be reached in sub-
ject's blood plasma since caffeine reaches peak plasma 
levels approximately one hour after ingestion (Axelrod & 
Riechenthal (1953). Conversely, Chou (1992) reported caf-
feine's half-life (time required for the drug to be elimi-
nated) to range from 2 to 12 hours with an average half-life 
of 4 to 6 hours. Therefore, the results reported by all 
three of the previous studies could possibly be misrepre-
sented due to the effects of time on caffeine. Lower doses 
comparable to 2.5 mg./kg. bwt. were not tested. And, in the 
studies with comparable caffeine intake to the 5.0 mg./kg. 
bwt. dose, repeated measurements were taken hours after 
ingestion which collectively could have skewed the test 
results. 
The dosage of caffeine ingested is another difference 
among the previous studies and the current study that could 
play a significant role in interpreting these results. In 
the studies previously cited (Roback et al., (1952); King & 
Henry (1992); and Kerr et al., 1991), researchers adminis-
tered blanket doses of caffeine to subjects. Roback et al. 
(1952) administered a single dose of 30 mg. of caffeine. 
King and Henry (1992) administered 400 mg. while Kerr et al. 
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(1991) administered 250 mg. to each subject. In a 150 pound 
subject (68.18 kg.), a 2.5 mg./kg. bwt. dose of caffeine is 
equal to 170.5 mg. and a 5.0 mg./kg. bwt. dose is equal to 
340.9 mg. of caffeine. Although the dose administered by 
Roback et al. (1952) represents a vary low caffeine dose, 
both the blanket doses of the latter two studies (Kerr et 
al., 1991; King & Henry, 1992) represent caffeine intake at 
the upper range of the current study. The dosage utilized 
in King and Henry's study (1992) exceeds the caffeine intake 
of the current study determined by body weight. Therefore, 
since none on the previous studies reported an increase in 
flicker fusion discrimination as did the current study at 
2.5 mg./kg. bwt., it could be theorized that in the first 
study (Roback et al., 1952) the caffeine dose was too low 
and the caffeine dose in the latter two studies (King and 
Henry, 1992; Kerr et al., 1991) was too high. Again, as 
with luminescent threshold, flicker fusion discrimination 
appears to be dose specific based on the current study's 
results. 
Variations among the studies (e.g., statistical analy-
ses, test apparatus, time between caffeine ingestion and 
testing, and caffeine dosages) continue to make it difficult 
to compare the current study to previous studies. With 
further study and uniformity of protocols, more conclusive 
information concerning caffeine's visual effects will be 
discovered. Specifically, additional research is required 
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to clarify the effect of caffeine on flicker fusion discrim-
ination. 
Repetition Blindness. Previous studies examining the 
effects of caffeine on repetition blindness do not exist. 
In the current study, however, the Newman-Keuls post hoc 
analysis reported a significant decrease in repetition 
blindness at the 2.5 mg./kg. bwt. caffeine dose when pre-
test and post-test mean scores were compared. A computer-
ized program created by Dr. Larry Hochhaus (Hochhaus and 
Mihura, 1993) was utilized to test caffeine's effects on the 
subject's ability to identify a target word after being 
shown a prime word. Although Dr. Hochhaus has utilized this 
program to examine self-inhibition as a possible cause of 
repetition blindness, it has never been utilized in mea-
suring the effect of caffeine on repetition blindness. In 
addition, the program (particularly the time between prime 
and target) was modified from its' original form for this 
study. 
Comparisons with previous research can not be made 
since no studies concerning the effect of caffeine on repe-
tition blindness are available. However, secobarbital was 
found to adversely effect perceptual processing (Logsdon et 
al., 1984); therefore, caffeine, a stimulant of the central 
nervous system, could theoretically improve visual perfor-
mance. Keeping this in mind, along with information uncov-
ered while exploring caffeine's effects on luminescent 
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threshold comparisons and flicker fusion discrimination, 
efforts were made to devise a way to explore the effects of 
caffeine on repetition blindness. Significance did occur in 
the repeated measures ANOVA and Newman-Keuls post hoc analy-
sis conducted on the repetition blindness data. A signifi-
cant difference was reported between the pre and post-test 
mean scores of the 2.5 mg./kg. bwt. caffeine dose. Repeti-
tion blindness, as with luminescent threshold and flicker 
fusion, appears to be dose dependent on caffeine. 
CHAPTER V 
SUMMARY, FINDINGS, CONCLUSIONS, AND 
RECOMMENDATIONS FOR FURTHER STUDY 
Summary 
Twenty-three undergraduate college students ranging in 
age from 19 to 43 were tested for the effects of selected 
doses of caffeine on luminescent threshold comparisons, 
flicker fusion discrimination, and repetition blindness. 
Each subject was pre-tested; given either O mg./kg. bwt., 
2.5 mg./kg. bwt., or 5.0 mg./kg. bwt.; and post-tested on 
three separate occasions. Approximately 60 minutes after 
the ingestion of either the placebo or caffeine dose the 
post-test was administered repeating the pre-test procedure. 
A different dose of caffeine was administered following each 
weekly pre-test. As a result, upon completion of the three 
week testing period, every subject had received all three 
doses of caffeine. 
Findings 
The current study and its' findings represent an 
addition to the existing body of knowledge examining caf-
feine's effects on vision. However, it is obvious that much 
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work is left to be done in exploring this stimulants' visual 
effects. Different statistical analyses, apparatus, caf-
feine doses and time lapse between caffeine ingestion and 
post-test are just some of the reasons it is so difficult to 
compare the current results with previous findings. Even 
though caffeine is a central nervous system stimulant and 
has this same pharmacological effect on the rest of the body 
(Koetting, 1977), caffeine's effects on vision remain 
unclear despite years of research. Caffeine appears to 
impact vision by effecting the cerebral cortex, as well as, 
by directly effecting the eye itself. However, there 
continues to be many unanswered questions surrounding caf-
feine's effects on vision. 
Repeated measures ANOVAs have customarily been the 
analysis of choice for exploring caffeine's effects on 
physiological parameters. When examining each visual test 
separately, the repeated measures ANOVAs and post hoc analy-
ses identified statistically significant differences between 
treatments (placebo, 2.5 mg./kg. bwt. caffeine, and 5.0 
mg./kg. bwt. caffeine.). 
Significance was found across the 2.5 mg./kg. bwt. and 
5.0 mg./kg. bwt. caffeine doses at low luminescence when 
making luminescent threshold comparisons. Moderate caffeine 
consumption (2.5 mg./kg. bwt.) at low luminescence resulted 
in a greater fluctuation in subjects' pre to post-test 
responses compared to the responses at the 5.0 mg./kg. bwt. 
caffeine dose. 
Findings at moderate luminescence were significant 
across the 2.5 and 5.0 mg./kg. bwt. caffeine levels and 
across the placebo and 5.0 mg./kg. bwt. caffeine dose. 
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A higher level of caffeine (5.0 mg./kg. bwt.) resulted in 
greater fluctuations between pre and post-test luminescent 
threshold responses compared to both the placebo and the 2.5 
mg./kg. bwt. dose. 
Caffeine appears to have had no significant effect at 
high luminescence. Although significant findings were 
reported across treatments at both low and moderate lumines-
cence, data collected at high luminescence did not produce 
significant fluctuations in pre to post-test scores at any 
level of treatment. 
Significance was also reported at the 2.5 mg./kg. bwt. 
caffeine dose between pre and post-test mean scores describ-
ing flicker fusion. These findings indicate that flicker 
fusion discrimination increased significantly following con-
sumption of 2.5 mg./kg. bwt. caffeine. As a result, flicker 
fusion was postponed after moderate caffeine consumption. 
The results of the repetition blindness analyses 
reflect a significant difference in pre to post-test scores 
after consumption of the 2.5 mg./kg. bwt. caffeine dose. A 
greater fluctuation in responses was reported following 
ingestion of the moderate dose of caffeine {2.5 mg./kg. 
bwt.) compared to pre to post-test responses of the other 
two treatments. Subjects were able to correctly identify 
more target words following moderate caffeine consumption 
(2.5 mg./kg. bwt.) compared to the other caffeine levels. 
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A similar pattern of significant and nonsignificant 
findings occurred following consumption of a particular dose 
of caffeine in the Newman-Keuls pot hoc analyses. Signifi-
cant fluctuations in luminescent threshold comparisons 
occurred after consuming 2.5 mg./kg. bwt. caffeine at low 
luminescence and similar effects occurred at moderate 
luminescence after consumption of 5.0 mg./kg. bwt. caffeine. 
Significance was also detected between pre and post-test 
responses after consumption of 2.5 mg./kg. bwt. caffeine for 
both flicker fusion discrimination and repetition blindness. 
This seems to indicate that caffeine's effects may be dose 
related. Although significant subject variability may have 
influenced the outcomes to some degree, the phenomenon of 
the moderate caffeine dose (2.5 mg./kg. bwt.) may be the 
most influential across virtually all visual tests is a 
pattern worth noting. 
Another important inference may be made concerning 
caffeine's effects on luminescent threshold. In making 
luminescent threshold comparisons, it seems as the intensity 
of the light stimulus increases so must the quantity of 
caffeine increase to result in significant differences in 
pre to post-test responses. At low luminescence, the 2.5 
mg./kg. bwt. caffeine dose caused a significant difference 
87 
between pre and post-test responses. At moderate lumines-
cence, the 5.0 mg./kg. bwt. dose caused significant fluctua-
tions in scores. And, at high luminescence, no significant 
findings were revealed. It seems that the eye may be more 
sensitive to light at higher levels of luminescence which 
requires a higher dose of caffeine to elicit a significant 
response. Theoretically, it would seem that a higher dose 
of caffeine (e.g., 7.5 mg./kg. bwt.} would be required to 
elicit a significant fluctuation in pre to post-test scores 
as high luminance. 
Conclusions 
Based on the results of this study, it was concluded 
that moderate levels of caffeine did significantly impact 
vision among these subjects and, in some cases, improved 
visual performance. The 2.5 mg./kg. bwt. dose of caffeine 
was associated with significant fluctuations in pre to post-
test responses when making luminescent threshold comparisons 
at low luminescence when contrasted to the effects of the 
5.0 mg./kg. bwt. dose. Similarly, for both flicker fusion 
discrimination and repetition blindness, the 2.5 mg./kg. 
bwt. dose provided significant results. Specifically, for 
these two visual tests, the 2.5 mg./kg. bwt. dose was 
associated with improved performance; postponed flicker 
fusion and decreased repetition blindness. No significance 
was reported after ingestion of the high caffeine dose (5.0 
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mg./kg. bwt.) in any of the post hoc analyses which reported 
significance only at the 2.5 mg./kg. bwt. dose. Perhaps a 
dose related response exists since the higher dose of 
caffeine did not result in proportionate increases in 
fluctuations of scores (luminescent threshold comparisons) 
or improvements in performance (flicker fusion discrimina-
tion and repetition blindness). 
A second conclusion was made based on the results of 
the luminescent threshold comparisons' post hoc analyses. 
It was concluded that higher levels of caffeine were re-
quired to elicit significant fluctuations in pre to post-
test scores in response to higher intensities of lumines-
cence. Caffeine seems to affect visual comparisons depen-
dent on the caffeine level and the intensity of light. The 
eye, at brighter light intensities, appeared to be more 
sensitive and required more caffeine to elicit significant 
results. At low luminescence, the 2.5 mg./kg. bwt. dose of 
caffeine resulted in more diverse pre to post-test scores 
than the 5.0 mg./kg. dose. At moderate luminescence, the 
5.0 mg./kg. bwt. dose resulted in more diverse pre to post-
test scores compared to both the placebo and the 2.5 mg./kg. 
bwt. dose. And, at high luminescence, no significant 
findings were reported. At moderate luminescence, more 
caffeine (5.0 mg./kg. bwt.) was needed to elicit significant 
results compared to the caffeine (2.5 mg./kg. bwt.) associ-
ated with significant findings at low luminescence. Theo-
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retically, higher doses of caffeine (e.g., 7.5 mg./kg. bwt.) 
may further affect luminescent threshold comparisons at high 
luminescence. 
These conclusions should be of importance to the 
general public and in particular for people who maintain 
occupations that require and demand visual accuracy. Some 
occupations which would be affected by increased visual 
acuity (or lack there of) include: pilots, air traffic 
controllers, professional athletes, computer programmers, 
and data entry. If caffeine's effect on vision is deter-
mined by dose and/or if the intensity of light impacts 
caffeine's visual effects, "the public" would benefit both 
personally and professionally from this knowledge. 
Recommendations for Further Study 
Modifications are often made in methodologies, appara-
tus, and procedures in research designs to validate prior 
studies, reveal additional information, recognize relation-
ships, and elucidate potential implications for further 
study. Particularly, for experimental research, this need 
is imperative to gain further knowledge concerning implica-
tions of such findings and more importantly for application 
of results. This author has several suggestions for re-
searchers conducting future studies that examine the effects 
of caffeine on visual performance. These recommendations 
include changes involving the subjects, quantities of caf-
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feine administered, procedures implemented, and the appara-
tus utilized in measuring caffeine's visual effects. 
Modification of the subject pool may increase the 
potential for statistically significant differences in this 
study. The author suggests increasing the number of sub-
jects in future studies. By using more subjects, the power 
of the statistical tests would increase which would yield a 
more sensitive analysis of data. Moreover, inclusion of 
subjects that are truly caffeine naive (<100 mg. caffeine 
consumed daily) would eliminate the potential for experienc-
ing symptoms of caffeine tolerance or withdrawal which 
generally confound results. 
Alterations in caffeine dosage may need to be included 
in future studies to provide adequate information to under-
stand caffeine's effect on vision. More of a trend may 
develop by adding additional levels of caffeine. If the eye 
is more sensitive to brighter light (higher luminescence), 
more caffeine may be needed to elicit a significant visual 
response. By including at least one or possibly two more 
dosages of caffeine that is higher than 5.0 mg./kg. bwt. 
(e.g., 7.5 mg./kg. bwt. and 10 mg./kg. bwt.), more of a dose 
response curve and/or the saturation level in the subjects 
may develop which may allow researchers to detect additional 
differences. The addition of these extra intervals may be 
prohibitive, however, due to caffeine's side effects (irri-
tability, nervousness, and tremulousness) reported for high 
levels of caffeine intake (>600 mg.). As a result, a more 
thorough medical screening and observation of subjects 
following caffeine consumption by medical personnel may be 
warranted. 
91 
Further studies may focus on individual components of 
the present study given its' complexity (e.g., three levels 
of caffeine; three different visual tests; and one of the 
visual tests, luminescent threshold comparisons, tested 
three different intensities of light). For example, a study 
could be developed to assess each independent variable 
(e.g., caffeine dosages) separately. In this way, the study 
is simplified, more control is exercised on the test vari-
ables, and the power of the test increases. In addition, 
further study examining luminescent threshold comparisons 
could identify specific threshold responses to various 
caffeine levels. 
The specific apparatus utilized in this study have not 
been implemented in prior studies examining caffeine's 
effect on vision. The author believes it would be interest-
ing to repeat this type of testing utilizing the same appa-
ratus to verify/clarify the current findings. Specifically, 
with regard to repetition blindness, the author suggests one 
change. By decreasing the amount of time the target word is 
flashed on the computer screen (e.g., from 17 ms. to 10 
ms.), difficulty in identifying the target word would be 
increased. This would place increased demands on the subje-
cts' visual response and further accentuate the dose re-
sponse curve mentioned earlier. 
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Individual's Consent for Participation in a Research Project 
Oklahoma State University 
I, 
this study entitled: 
, voluntarily agree to participate in 
~--,,---,:--~---,-......--=--:-~. Flicker Fusion, Visual Threshold, and 
Repetition Blindness 
feine) Ingestion. 
in Response to Trimethylxanthine (Caf-
1. PURPOSE: This study involves research that will be 
carried out under the supervision of Bert H. Jacobson, Ed.D. 
(principal investigator) an4 Darla Fent, Graduate Student. 
The purpose of this study will be to ascertain the effects 
of 2.5 mg./kg. bwt. and 5.0 mg./kg. bwt. caffeine on three 
aspects of visual acuity: flicker fusion, visual threshold, 
and repetition blindness. In the realm of many occupations 
such qualities are often necessary and/or vital. Given that 
one cup of coffee contains 100 mg. caffeine, it is safe to 
assume that many professionals consume up to 400 mg. caf-
feine prior to or during work time. However, casual con-
sumption is not all in one dose. This study will attempt to 
find if deleterious effects follow a single dose of 2.5 
mg./kg. bwt. and 5.0 mg./kg. bwt. caffeine consumption. 
2. STATUS OF INVESTIGATIONAL DRUG PROCEDURES: Caffeine may 
alter blood pressure, heart rate, respiration and metabolic 
rate. Caffeine may also induce _tremors, nervousness, and 
anxiety. 
3. DESCRIPTION OF STUDY: This study will involve a pre-
screening consisting of blood pressure and heart rate. 
Additionally a medical history questionnaire containing the 
following items will be administered: oral contraceptive 
use, medication use, current illnesses, pregnancy, hang 
over, history of heart disease, etc •.. Further, a caf-
feine consumption questionnaire will be administered to 
ascertain the average amount of caffeine consumed per day 
and per week. Any subject indicating a blood pressure 
reading above 140 mm. Hg. systolic pressure and/or 90 mm. 
Hg. diastolic pressure and/or tachycardia will be eliminat-
ed from the study. Also, any positive response on the 
medical history questionnaire may result in elimination. 
Subjects will be asked to fast from food for five (5) 
hours and fast from caffeine for 48 hours prior to testing. 
Subjects will be pre-tested for flicker fusion, visual 
threshold, and repetition blindness. Following the pre-
test, each subject will ingest one of three capsules con-
taining: 1) o mg. caffeine, 2) 2.5 mg./kg. bwt., or 3) 
5.0 mg./kg. bwt. caffeine utilizing a double blind format. 
Following a one (1) hour waiting period, all subjects will 
be post-tested using the pre-test protocol. 
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The full duration of this study will take approximately 
one and a half (1.5) hours. 
I understand that I will be given O mg., 2.5 mg./kg. 
bwt., 5.0 mg./kg. bwt. caffeine. Neither I nor the investi-
gator will know which dosage I have been administered during 
each test but that information can be obtained if necessary. 
4. BENEFITS: No direct benefit in the consumption of 
caffeine may be expected. However, observable physical 
changes may lead to a change in attitude toward caffeine 
consumption and a greater awareness of products containing 
caffeine may ensue. 
5. POSSIBLE RISKS: Caffeine ingestion in the quantities 
described in this study may increase nervousness, irritabil-
ity and anxiety. Respiration, blood pressure and heart rate 
may also be magnified. Additionally nausea may appear if 
the meal following caffeine consumption includes spicy 
and/or greasy food. STAY AWAY FROM PIZZA! 
If you become nauseous or feel ill, you will be re-
tained for observation and transported to the University 
Health Center. 
I recognize that the primary risk is the possibility of 
experiencing some side effects. Those that have been ob-
served in the past for caffeine consumption include: 
Hyperactivity 
Upset stomach 
Nervousness 
If I have any side-effects, I will report them immediately 
to the investigator, my physician or his/her associates. If 
side-effects are severe, I may be removed from the study. 
6. ALTERNATE PROCEDURES: None 
7. SUBJECT ASSURANCES: Whereas no assurance can be made 
concerning results that may be obtained (because results 
from investigational studies cannot be predicted with cer-
tainty), the principal investigator, will take every precau-
tion consistent with best scientific practice. 
By signing this consent form, I acknowledge that my 
participation in this study is voluntary. I also acknowl-
edge that I have not waived any of my legal right or re-
leased this institution form liability for negligence. 
I may revoke my consent and withdraw from this study at 
any time without penalty or loss of benefits. My treatment 
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by, and relations with the investigators and staff at Okla-
homa state University, now and in the future, will not be 
affected in any way if I refuse to participate, or if I 
enter the program and later withdraw. 
Records of this study will be kept confidential with 
respect to any written or verbal reports making it impossi-
ble to identify me individually. All records will be held 
in a locked file belonging to the principal investigator. 
If I have any questions about my rights as a research 
subject, I may take them to the Office of University Re-
search Services, 001 Life Sciences East. Phone: 744-5700. 
a. SIGNATURES: 
Date Research Subject 
Date Witness 
Date Principal Investigator 
Any questions regarding the research may be addressed 
to Bert Jacobson, Principal Investigator. 102 Colvin Cen-
ter. Phone: 744-5493. 
Subjects will receive a copy of this consent form 
following the investigation. 
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Name 
Date 
CAFFEINE RESEARCH QUESTIONNAIRE 
Caffeine Consumption History 
Vital Statistics* Medical History 
Age __ Sex Wt. 
of Birth 
PRE POST 
Ht. 
---
HR b/min b/min 
--------
BP I I 
Caffeine Consumation History: 
Coffee: Cups/day avg. 
Soft Drinks {Coke, Dr. Pepper, Mt. Dew, etc.)/day avg. 
Tea: Cups/day Glasses/day 
-----Other: Explain 
How does caffeine affect you? 
Medical History: 
Have you experienced or know 
Heart trouble 
Intestinal disorders 
High Heart Rate 
Mental/Emotional Disorders 
of: {Respond "YES" or 
Stomach disorders 
High Blood Pressure 
Kidney Disorders 
---Fibrocystic Breast Disease 
Do you wear corrective lenses or contacts? 
Do you smoke? 
Do you think you are pregnant? 
Are you currently taking oral contraceptives? 
"NO". ) 
Are your presently on medication? If so, explain 
Vital Study: Criteria 
Are your suffering from a hangover? 
Are you suffering from lack of sleep? 
Have you fasted for 5 hours? 
Last meal was hrs. ago. 
Last caffeine was consumed hrs. ago 
in the form of 
TESTING WEEK NUMBER 
-------
DATE OF 
TIME OF 
TIME OF 
WEEK# 
TESTING: Pre-test ; Post-test 
CAFFEINE INGESTION FOR STUDY 
SUBJECT#-----------
--------
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CAFFEINE CONTENT OF COMMON BEVERAGES, FOODS, & MEDICATIONS 
* Caffeine Content {mg) in Selected 12 
Afri-Cola 
Jolt 
Sugar-Free Mr. Pibb 
Mountain Dew 
Diet Mountain Dew 
Mello Yellow 
Tab 
Coca-Cola 
Diet Cola 
Shasta Cola 
Shasta Diet Cola 
Mr. Pibb 
Dr. Pepper 
Pepsi Cola 
Diet Pepsi 
RC Cola 
Diet RC 
Canada Dry Cola 
7 Up 
* National Soft Drink Association. 
oz. Sodas: 
100.0 mg(?) 
71.2 
58.8 
55.0 {O in Canada) 
55.0 
52.8 
46.8 
45.6 
45.6 
44.4 
44.4 
40.8 
39.6 
37.2 
35 •. 4 
36.0 
36.0 
30.0 
0 
* Caffeine Content {mg) in a 7 oz. cup of coffee\tea: 
Drip 115-175 mg 
Espresso (1.5 - 2 oz.) 100 
Brewed 80-135 
Instant 65-100 
Decaf, brewed 3-4 
Decaf, instant 2-3 
Tea, iced {12 oz.) 70 
Tea, brewed, imported 60 
Tea, brewed, U.S. 40 
Tea, instant 25-15-0 
* Bunker, L., & Mcwilliams, M. (1979). Caffeine content 
of common beverages • =-J-=o-=u=r __ n=a=l........._.o"""f ..... · __ t__ h __ e___.Am-==e=r=1=-· c __ a __ n=-=-D __ i __ e-=t-=e __ t-=i.__,c 
Association. 74. 28-32. 
* Other data on caffeine {amounts expressed in mg): 
Chocolate cake {l slice) 20-30 mg 
"Dristan" (Cold relief) 30 
"Anacin" (Pain relief) 32 
"Midol" (Pain relief) 32.4 
"Excedrin" {Pain relief) 65 
"Nodoz" {Stimulant) 100 
"Vivarin" {Stimulant) 200 
* Caffeine: How to consume less. (1981, October). Consum-
er Reports. pp. 597-599. 
* Health Letter Associates (1990). The Daily Dose. Berke-
ley Wellness Letter, University of California. 
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REPETITION BLINDNESS RESPONSE SHEET 
SUBJECT NAME SUBJECT NUMBER 
WEEK 1 -- PRE-TEST SUBJECT #1/DEMO.RB.A 
BLOCK 1 BLOCK 5 
1. ROOM R. ROOM 33. BOTH U. LAST 
2. SIDER. SIDE 34. LIFE U. YEAR 
3. NEED U. FOUR 35. LONG R. LONG 
4. GIVER. GIVE 36. WORK R. WORK 
5. FORM U. CASE 37. VERY R. VERY 
6. FACER. FACE 38. HERE u. KNOW 
7. FELT U. BEST 39. MAKE R. MAKE 
8. EVER U. WANT 40. SAME u. COME 
BLOCK 2 
9. WITH R. WITH 
10. FROM R. FROM 
11. THIS R. THIS 
12. HAVER. HAVE 
13. WHEN U. WHAT 
14. BEEN U. SAID 
15. THEY U. WILL 
16. WERE U. MORE 
BLOCK 3 
17. INTO R. INTO 
18. ONLY R. ONLY 
19. THAN R. THAN 
20. THEM R. THEM 
21. THEN U. EVEN 
22. TIME U. OVER 
23. SUCH U. MOST 
24. SOME U. LIKE 
BLOCK 4 
25. MUST R. MUST 
26. WELL U. GOOD 
27. YOUR U. JUST 
28. MANY R. MANY 
29. MUCH U. EACH 
30. BACK U. DOWN 
31. MADER. MADE 
32. ALSO R. ALSO 
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REPETITION BLINDNESS RESPONSE SHEET (continued) 
SUBJECT NAME SUBJECT NUMBER 
WEEK 1 -- POST TEST SUBJECT #2/DEMO. RB. B 
BLOCK 1 BLOCK 5 
1. FORM U. CASE 33. MAKER. MAKE 
2. NEED U. FOUR 34. BOTH U. LAST 
3. SIDER. SIDE 35. LONG R. LONG 
4. EVER U. WANT 36. HERE R. HERE 
5. GIVER. GIVE 37. WORK R. WORK 
6. ROOM R. ROOM 38. LIFE U. YEAR 
7. FACER. FACE 39. KNOW U. CAME 
8. FELT U. BEST 40. SAME U. COME 
BLOCK 2 
9. WILL U. INTO 
10. BEEN U. SAID 
11. THEY R. THEY 
12. FROM R. FROM 
13. WHEN U. WHAT 
14. THIS R. THIS 
15. HAVER. HAVE 
16. WERE U. MORE 
BLOCK 3 
17. THEM R. THEM 
18. ONLY R. ONLY 
19. THEN U. EVEN 
20. SOMER. SOME 
21. THAN R. THAN 
22. TIME U. OVER 
23. LIKE U. MADE 
24. SUCH U. MOST 
BLOCK 4 
25. BACK R. BACK 
26. MUST R. MUST 
27. DOWN U. VERY 
28. WELL U. GOOD 
29. ALSO R. ALSO 
30. YOUR U. JUST 
31. MANY R. MANY 
32. MUCH U. EACH 
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REPETITION BLINDNESS RESPONSE SHEET (continued) 
SUBJECT NAME SUBJECT NUMBER 
WEEK 2 -- PRE-TEST SUBJECT #3/DF.M.O. RB. C 
BLOCK 1 BLOCK 5 
1. GIVER. GIVE 33. SAME U. COME 
2. FORM U. CASE 34. LIFE U. YEAR 
3. FELT U. BEST 35. BOTH R. BOTH 
4. SIDER. SIDE 36. KNOW U. CAME 
5. EVER U. WANT 37. HERE R. HERE 
6. FACER. FACE 38. WORK R. WORK 
7. NEED U. FOUR 39. LONG R. LONG 
8. ROOM R. ROOM 40. LAST U. USED 
BLOCK 2 
9. BEEN U. SAID 
10. MORE U. THAN 
11. FROM R. FROM 
12. THEY R. THEY 
13. HAVER. HAVE 
14. WILL U. INTO 
15. WERE R. WERE 
16. WHEN U. WHAT 
BLOCK 3 
17. THF.M. R. THF.M. 
18. LIKE U. MADE 
19. SUCH U. MOST 
20. TIMER. TIME 
21. OVER U. ALSO 
22. SOME R. SOME 
23. ONLY R. ONLY 
24. THEN U. EVEN 
BLOCK 4 
25. DOWN U. VERY 
26. YOUR U. JUST 
27. BACK R. BACK 
28. WELL U. GOOD 
29. MUST R. MUST 
30. MANY R. MANY 
31. EACH U. MAKE 
32. MUCH R. MUCH 
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REPETITION BLINDNESS RESPONSE SHEET (continued) 
SUBJECT NAME SUBJECT NUMBER 
WEEK 2 -- POST TEST SUBJECT #4/DEMO. RB. D 
BLOCK 1 BLOCK 5 
1. ROOM R. ROOM 33. SAME U. COME 
2. EVER U. WANT 34. YEAR U. TAKE 
3. NEED U. FOUR 35. LIFER. LIFE 
4. FELT U. BEST 36. LONG R. LONG 
5. SIDER. SIDE 37. LAST U. USED 
6. FACER. FACE 38. HERE R. HERE 
7. FORM U. CASE 39. BOTH R. BOTH 
8. GIVER. GIVE 40. KNOW U. CAME 
BLOCK 2 
9. WHEN u. WHAT 
10. WILL u. INTO 
11. HAVE R. HAVE 
12. MORE u. THAN 
13. THEY R. THEY 
14. WERE R. WERE 
15. SAID u. THEM 
16. BEEN R. BEEN 
BLOCK 3 
17. EVEN u. MANY 
18. TIME R. TIME 
19. ONLY R. ONLY 
20. SOMER. SOME 
21. SUCH U. MOST 
22. OVER U. ALSO 
23. THEN R. THEN 
24. LIKE U. MADE 
BLOCK 4 
25. MUST R. MUST 
26. DOWN U. VERY 
27. MUCH R. MUCH 
28. WELL U. GOOD 
29. JUST U. WORK 
30. EACH U. MAKE 
31. YOUR R. YOUR 
32. BACK R. BACK 
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REPETITION BLINDNESS RESPONSE SHEET (continued) 
SUBJECT NAME SUBJECT NUMBER 
WEEK 3 -- PRE-TEST SUBJECT #5/DEMO. RB. E 
BLOCK 1 BLOCK 5 
1. FACER. FACE 33. COME u. HOME 
2. SIDER. SIDE 34. SAME R. SAME 
3. GIVER. GIVE 35. KNOW u. CAME 
4. FELT U. BEST 36. BOTH R. BOTH 
5. FORM U. CASE 37. YEAR U. TAKE 
6. NEED U. FOUR 38. HERE R. HERE 
7. ROOM R. ROOM 39. LIFER. LIFE 
8. EVER U. WANT 40. LAST U. USED 
BLOCK 2 
9. WHEN R. WHEN 
10. BEEN R. BEEN 
11. SAID U. THEM 
12. WERE R. WERE 
13. THEY R. THEY 
14. WILL U. INTO 
15. WHAT U. ONLY 
16. MORE U. THAN 
BLOCK 3 
17. MOST U. MUST 
18. SUCH R. SUCH 
19. LIKE U. MADE 
20. EVEN U. MANY 
21. THEN R. THEN 
22. SOMER. SOME 
23. TIMER. TIME 
24. OVER U. ALSO 
BLOCK 4 
25. BACK R. BACK 
26. JUST U. WORK 
27. DOWN U. VERY 
28. GOOD U. LONG 
29. YOUR R. YOUR 
30. WELL R. WELL 
31. MUCH R. MUCH 
32. EACH U. MAKE 
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REPETITION BLINDNESS RESPONSE SHEET (continued) 
SUBJECT NAME SUBJECT NUMBER 
WEEK 3 -- POST TEST SUBJECT #6/DEM.O RB. F 
BLOCK 1 BLOCK 5 
1. GIVER. GIVE 33. KNOW R. KNOW 
2. ROOM R. ROOM 34. SAME R. SAME 
3. NEED U. FOUR 35. COME U. HOME 
4. FELT U. BEST 36. YEAR U. TAKE 
5. FORM U. CASE 37. CAME U. WENT 
6. SIDER. SIDE 38. LAST U. USED 
7. EVER U. WANT 39. LIFER. LIFE 
8. FACER. FACE 40. BOTH R. BOTH 
BLOCK 2 
9 •. SAID U. THEM. 
10. WERE R. WERE 
11. WHAT U. ONLY 
12. INTO U. SOME 
13. WILL R. WILL 
14. MORE U. THAN 
15. WHEN R. WHEN 
16. BEEN R. BEEN 
BLOCK 3 
17. SUCH R. SUCH 
18. LIKE R. LIKE 
19. TIME R. TIME 
20. MOST u. MUST 
21. THEN R. THEN 
22. OVER U. ALSO 
23. EVEN U. MANY 
24. MADE U. BACK 
BLOCK 4 
25. YOUR R. YOUR 
26. EACH U. MAKE 
27. WELL R. WELL 
28. JUST U. WORK 
29. GOOD U. LONG 
30. VERY U. HERE 
31. DOWN R. DOWN 
32. MUCH R. MUCH 
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RAW DATA RECORD SHEET 
Flicker Fusion, Visual Threshold, and Repetition Blindness 
in Response to Trimethylxanthine (Caffeine) Ingestion 
Subject Name _______ _ Subject Number 
-------
Date of Birth Week Number 
-------
-------~ 
PRE POST 
Flicker Fusion Flicker Fusion 
setting of Response Setting of Response 
1. 1. 
2. 2. 
3. 3. 
Visual Threshold Visual Threshold 
Standard Response Standard Response 
1. 140 1. 140 
2. 290 2. 290 
3. 220 3. 220 
Repetition Blindness Repetition Blindness 
Correct Incorrect Correct Incorrect 
1. 1. 
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VERBAL INSTRUCTIONS FOR TESTING 
Flicker Fusion Discrimination 
Flicker Fusion is defined as the point where the frequency 
of a flickering light is no longer discernable. 
1. Please sit in front of the display unit and note the two 
stimulus windows from which light will be emitted. 
2. Once the overhead lights are dimmed to facilitate visual 
perception, you will observe a flickering light in the 
display unit. 
3. Your objective is to identify the point in time in which 
the light no longer flickers. In other words, you are 
identifying the earliest point at which the successive 
stimuli are perceived as completely fused. 
4. This process will be performed three times. 
Luminescent Threshold Comparisons 
Luminescent Threshold is defined as the point in which the 
eye can discern differences in the intensity of light acting 
as a stimulus. 
1. Please sit directly 
Apparatus. (NOTE: 
NOT BE ABLE TO SEE 
DIALS.) 
in front of the Light Discrimination 
IT IS IMPERATIVE THAT THE SUBJECT 
EITHER OF THE INTENSITY ADJUSTMENT 
2. This is a light discrimination test. The light on the 
unit adjacent to your dominant hand is variable in 
intensity. The other light is fixed in intensity and 
is called the standard. 
3. Once the lights are dimmed to facilitate visual percep-
tion, you will use your dominant hand to adjust the 
light intensity dial located on that side of the unit. 
4. Your job is to adjust the variable light so that it 
LOOKS equal in intensity to the standard. 
5. This process will be performed three times with the 
standard being set to a maximal, minimal, or median 
intensity for each trial. 
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VERBAL INSTRUCTIONS FOR TESTING (continued} 
Repetition Blindness 
Repetition blindness is defined as the inability to identify 
a second exposure to a repeated word or identification of a 
novel word following an initial exposure to a prime word. 
1. Please sit in front of the computer screen and keyboard. 
2. This exercise consists of forty trials. The first eight 
trials are considered "practice trials" and the data 
generated in these practice trials will not be consid-
ered in this study. Each trial begins when you depress 
the "space" bar. You may proceed at your own comfort-
able pace. 
3. For each trial, you will see the number of the trial 
displayed (e.g., Trial 1). Once the space bar is de-
pressed,you will briefly see a PRIME word, a four let-
ter word, flashed in all caps in the center of the 
screen. Then, slightly below this word, a pair of 
arrows will immediately be displayed pointing to the 
TARGET word, either the same word OR a different word, 
also flashed in all caps (e.g., ------>GIVE<------}. 
Each of the second, or target, words is then imme-
diately replaced with ampersands (e.g., &&&&&&&&&&&&&} 
and the next trial (e.g., Trial 2} is ready to begin. 
4. Your objective is to verbally identify both words in 
each trial. You will say the trial number followed by 
each PRIME and TARGET word. 
5. If you are unable to read either the prime or target 
word, verbally respond with the word "BLANK" and pro-
ceed to the next trial. 
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ANOVA Summary Tables 
ss DF MS F £ 
Low Luminescence 
Effect 905.26 2 452.63 3.62* .04 
Error 5503.23 44 125.07 
*Significant, p < .05. 
Moderate Luminescence 
Effect 1963.94 2 981.97 4.36* .02 
Error 9904.06 44 225.09 
*Significant, p < .05. 
High Luminescence 
Effect 496.55 2 248.28 1.86* .17 
Error 5859.45 44 133.17 
*Not significant, p > .05. 
Flicker Fusion 
Effect 477.15 5 95.43 7.24* .oo 
Error 1450.78 110 13.19 
*Significant, p < .05. 
Repetition Blindness 
Effect 278.59 5 55.72 3.47* .01 
Error 1766.58 110 16.06 
*Significant, p. < .05. 
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MEANS, STANDARD DEVIATIONS, AND PROBABILITIES 
FOR NEWMAN-KEULS POST HOC ANALYSES 
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Means, Standard Deviations, and Probabilities 
for Newman-Keuls Post Hoc Analyses 
Low Luminescence 
Factor 
1) Placebo or o mg./kg. bwt. 8.94 
16.70 
9.09 
2) 2.5 mg./kg. bwt. 
3) 5.0 mg./kg. bwt. 
Factor Probabilities 
8.91 
15.39 
6.76 
---------------------------------------------
*Significant, p < .05. 
Moderate Luminescence 
Factor 
1) Placebo 
2) 2.5 mg./kg. bwt. 
3) 5.0 mg./kg. bwt. 
Factor 
2. 
.06 
10.61 
11.91 
22.52 
Probabilities 
.96 
.03* 
8.39 
7.47 
22.83 
----------------------------------------------
1 2. .J. 
1 .77 .03* 
2. .02* 
.J. 
*Significant, p < .05. 
125 
126 
Means, Standard Deviations, and Probabilities 
for Newman-Keuls Post Hoc Analyses (Continued) 
High Luminescence 
Factor 
1) Placebo or o mg./kg. bwt. 7.74 
14.26 
10.30 
6.31 
20.07 
13.83 
2) 2.5 mg./kg. bwt. 
3) 5.0 mg./kg. bwt. 
No significance, p > .05. 
Flicker Fusion 
Caffeine 
0 
2.5 
5.0 
Pre-Test 
44.13 
38.74 
42.06 
Std. Dev. 
4.19 
6.77 
6.25 
*Significant, p < .05. 
Repetition Blindness 
Caffeine 
0 
2.5 
5.0 
Pre-Test 
1.43 
5.13 
1.65 
Std. Dev. 
4.18 
9.84 
4.27 
*Significant, p < .05. 
Post-Test 
44.31 
41.56 
42.66 
Std. Dev. P-Value 
5.13 
4.47 
4.51 
.87 
.01* 
.58 
Post-Test 
1.13 
1.83 
.96 
Std. Dev. P-Value 
4.14 
4.88 
3.95 
.80 
.01* 
.94 
APPENDIX I 
INSTITUTIONAL REVIEW BOARD (IRB) REVIEW FORM 
127 
OKLAHOMA STATE UNIVERSITY 
:INS flTOTIONAL REVIEW. BOARD 
HUMAN SUBJECTS REVIEW 
Date: 02-08-95 IRB#: ED-95-925 
Proposal Title: FLICKER FUSI0N7 VISUAL THRESHOLD, AND REPEIIIION 
BLINDNESS INRESPONSE·TO TRIME'IHYLXAN'I (~ INGESTION 
Principal Investigator(s): Bert Jacobson, Darla Fent 
Reviewed and Proc:es.!ed as: Expedited 
Approval Status Recommended by ·amewer(s): · Approved 
APPROVAL STATUS SUBJEC'l'TO REVJEWBYFOLL lNS'fflUl'IONALREVIEWBOARD ATNEXT 
MEET.ING. 
APPROVAL STATUS PERIOD V AI.ID FOR.ONE CALENDAR 'YEAR.AFIER WHICI A CONl'INUA'IION 
OR RENEWAL REQUEST JS REQUlRED TO BESUBMII"IED FOR BOARD APPROVAL. . . 
ANY MODIFICA'llONS TO APPROVED PR.OJEcrMCST ALSO BE SUBMrrIED FOR.APPR.OV AL. 
Cornrnents, Modificatioos/Conditions for Approval or Reasons 'for Defeml or Disapproval are u 
· follows: 
Revisions received and approved. 
Dam: Febtamy 23, 1995 
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